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 The research work presented in this dissertation describes tissue-specific 
functions of DNA methyltransferase 4 (an ortholog of the mammalian DNTM3B) 
during zebrafish hematopoiesis. Studies have implicated the involvement of DNA 
methylation in regulating hematopoiesis. Although DNA methylation by Dnmt1, 
Dnmt3a and Dnmt3b is required for HSC maintenance and self-renewal, the 
exact contributions of these enzymes in commitment of HSCs to different blood 
lineage precursors and terminal differentiation of these precursors into mature 
cells are not known.  
 Answers to this idea are important as deregulations of DNMT1, DNMT3A 
and 3B are known to be involved in hematopoietic diseases. Thus, a better 
understanding of the contributions of DNMTs in regulating normal hematopoiesis 
will help in designing better drugs for treating hematopoietic diseases that arise 
due to aberrant methylation patterns.  
 Chapter 1 is an introduction to DNA methylation and the enzymes, DNA 
methyltransferases that confer this methylation mark. This chapter summarizes 
literature from various model systems that allude to the requirement of DNA 
methyltransferases in a tissue-specific manner during normal development. 
 Chapter 2 describes the utility of zebrafish as a model system to study 
DNA methylation. Also, I have characterized the embryonic expression patterns, 
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morpholino knockdowns of DNA methyltransferases 4, 5, 6, 7, and 8 during 
zebrafish development. 
 Chapter 3 discusses the epigenetic regulation of mature blood lineages by 
DNA methyltransferase dnmt4 in zebrafish. Here we show that dnmt4 is 
expressed in the hematopoietic compartment of zebrafish embryos. Transient 
knockdown of dnmt4 confers terminal differentiation defects of the erythroid and 
the myeloid cells. The data discussed in this chapter juxtapose dnmt4 morphants 
as an amenable model system to study the molecular pathways affected in 
(Immunodeficiency Centromere instability and Facial anomalies) ICF type-1 
syndrome, which arises due to missense mutations in human DNMT3B. 
 Chapter 4 describes the epistatic relationship of dnmt4 with the tumor 
suppressor gene apc in regulating zebrafish hematopoiesis. 
 Chapter 5 presents the main conclusions of my dissertation work. I have 
























TABLE OF CONTENTS 
 
ABSTRACT........................................................................................................... iii 
LIST OF TABLES................................................................................................ viii 






 1 DNA METHYLATION IN DEVELOPMENT AND DISEASE ............ 1 
 
   1.1 DNA methylation ............................................................ 1 
   1.2 DNA methylation in context of CpG dinucleotides .......... 2 
    1.3 DNA methylation in development ................................... 4 
   1.4 DNA methylation in non- CpG dinucleotides context...... 6 
   1.5 DNA methylation and cell differentiation......................... 7 
   1.6 Mammalian DNA methyltransferases ............................ 8 
   1.7 DNA methylation in disease.......................................... 13 
   1.8 Conditional knockout models........................................ 17 
   1.9 Major unresolved questions.......................................... 25 
   1.10 Zebrafish as a model system...................................... 26 
   1.11 DNA methyltransferases in zebrafish ......................... 26 
   1.12 Preview ....................................................................... 28 
   1.13 References ................................................................. 37 
  
 2 CHARACTERIZING DE NOVO DNA METHYLTRANSFERASES IN 
ZEBRAFISH .................................................................................. 48 
   
   2.1 Introduction ................................................................... 48 
   2.2 Materials and methods ................................................. 52 
   2.3 Results.......................................................................... 53 
   2.4 Discussion .................................................................... 58 
   2.5 Acknowledgements ...................................................... 61 
   2.6 References .................................................................. 75 
 
  vii 
 3 DNA METHYLTRANSFERASE 4 REGULATES ZEBRAFISH 
HEMATOPOIESIS......................................................................... 78 
   
   3.1 Introduction ................................................................... 78 
   3.2 Materials and methods ................................................. 80 
   3.3 Results.......................................................................... 86 
   3.4 Discussion .................................................................... 98 
   3.5 Acknowledgements .................................................... 100 
   3.6 References ................................................................ 120 
 
 4 EPISTATIC RELATIONSHIP BETWEEN DNA 
METHYLTRANSFERASE 4 AND ADENOMATOUS POLYPOSIS 
COLI   ......................................................................................... 123 
 
   4.1 Introduction ................................................................. 123 
   4.2 Materials and methods ............................................... 127 
   4.3 Results........................................................................ 130 
   4.4 Discussion .................................................................. 132 
   4.5 Acknowledgements..................................................... 133 
   4.6 References ................................................................. 144 
    
 5 SUMMARY AND PERSPECTIVE ............................................... 146 
 
   5.1 Tissue-specific functions of dnmt, dnmt3 and dnmt4.. 146 
  5.2 Dnmt4 regulates zebrafish hematopoiesis.................. 147 
  5.3 Epistatic relationship of dnmt4 and RA pathway ........ 148 
  5.4 Epistatic relationship between dnmt and apc ............. 148 
  5.5 Future directions ......................................................... 149 





 A CHARACTERIZATION OF MBD PROTEINS.............................. 154                           
  
 B COMPARISON OF OVEREXPRESSION AND KNOCKDOWN OF 











          Table                                                                                                      Page   
 
 1.1 Interacting partners of DNA methyltransferases............................ 34 
 
 1.2   Phenotypes of murine knockouts of DNA methyltransferases ...... 35 
 
 1.3   Zebrafish dnmt mutants and morphants phenotypes .................... 36 
 
           2.1   Morpholino and primer sequences ................................................ 74 
 
 3.1   Morpholino and primer sequences .............................................. 118 
 
 3.2   Statistics of dnmt4 morphant phenotypes ................................... 119 
 
 4.1   Statistics of apc mutant phenotypes............................................ 142 
 
















GENE                  human gene 
Gene                   mouse gene 
gene                    zebrafish gene 
GENE                  human gene product 
GENE                  mouse gene product 






 A number of people have contributed to my thesis work. I would like to 
thank them for their interest, help, encouragement and support. First of all, I 
would like to thank Dr. David A. Jones and Dr. Bradley R. Cairns who have jointly 
mentored my graduate training.  
 Dave is a wonderful mentor and I will cherish my interactions with him 
both at work and outside lab. Scientifically, Dave encouraged me to develop 
independent thinking and provided ideas and suggestions whenever required. I 
have enjoyed being taught by him tremendously. The Jones lab is multicultural 
and diverse. Dave takes a lot of interest in the cultural backgrounds of his 
students and finds time to discuss such topics. I have thoroughly enjoyed the lab 
retreats and the Jones lab international potluck dinners. I have been very 
fortunate to have Brad as a graduate mentor. His scientific acumen and 
commitment to work are very inspiring. Brad has trained me a great deal with 
public speaking and critical thinking. He has helped me in obtaining reagents and 
help whenever required. Also, he helped me understand the bigger picture of my 
project. I have enjoyed attending the Cairns lab weekly meetings, lab paper 
celebrations, birthday cakes/pies and Christmas parties. 
 My committee members Nikolaus Trede, Dean Tantin and Donald Ayer 
have always taken keen interest in my work. I am grateful to them for their 
 xi 
support. I am thankful to Nick who has played a pivotal role in the progress of this 
project. He has been very supportive both with reagents and ideas. 
 I am also very thankful to the past and present members of the Jones, 
Cairns, and the Trede labs and my collaborators for their support, friendship and 
help. In particular I would like to acknowledge Fanuel, Graham, Stephanie, 
Smitha, Adam, Evan, Sarah, Mike, Kimble, and Ken. I would like to recognize the 
Core Facilities at the University of Utah for their services. 
 I would like to thank Barb, Tammy, Dee, Jess, Abby, Suzanne, and JoAnn  
for helping me with all my official departmental requirements .I am also thankful 
to Sharmistha, Purba, Kunal, Ranjeet, Ashutosh, Swati, Amar, Santoshi, 
Mugdha, Antara, Poulomi, Payal, Aditi, Rahila, Bhumi, and Shruti for their 
friendship. Also, this journey would not have been possible without the love and 
support of my siblings, Arshad, Shaheen, Nusrat, Abid and June.  
 I would like to remember my family members Pappa, Nanna, Baji Amma 
and Phuppa Abba who passed away in the last two years. Thank you for your 
love, support and blessings. My mother has always been my strength and 
inspiration. Thank you Mummy for your unending love and support. I am grateful 
to Mom, Dad, Brandy, Mandy and Sarah for their love and support.  
 Lastly I would like to thank my husband John, whose, love, support, 
encouragement and immense patients has given me hope and courage to face 




DNA METHYLATION IN DEVELOPMENT AND DISEASE 
 
1.1 DNA methylation  
 Generally in a multicellular organism with the exception of T and B 
lymphocytes that lose DNA sequences during VDJ recombination by deletions 
(1) most cells have exactly the same DNA sequences. In spite of this, the 
organism has various cell types that differ both in structure and in function. This 
cell specificity in part can be attributed to tissue-specific transcription factors and 
epigenetic changes, which are heritable modifications that occur outside the DNA 
sequence. Epigenetic mechanisms that regulate the genome include DNA (2-4) 
and histone (5) modifications, inclusion of histone variants (6) and noncoding 
RNAs (7,8).  
 Of these modifications DNA methylation plays a number of important 
functions in regulating the mammalian genome. Some of the biological functions 
that DNA methylation is implicated in are gene expression (9-11), cellular 
differentiation and development (12-14), genomic imprinting (15,16), X 
chromosome inactivation (17,18), silencing of retrotransposons and tandem 
repetitive sequences (19), preventing genomic instability (20), development of 
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autoimmune rheumatic diseases (21), cellular reprogramming (22), behavior 
(23), brain development (24), immune functions (25) and aging (26).  
 Importantly deregulations of the methylation machinery and aberrant DNA 
methylation patterns are associated with imprinting defects (15, 27), and various 
diseases like (Immunodeficiency Centromere instability and Facial anomalies) 
ICF syndrome (28) and various cancers (29). Unlike mutations or changes that 
involve alterations in DNA sequence, DNA methylation is a reversible process. 
This makes DNA methylation an important target for drug development. 
 
1.2 DNA methylation in the context of CpG dinucleotide  
 DNA methylation can occur in CG, CHG and CHH context (where H can 
be C, T or A). In mammals DNA methylation is usually referred to as the covalent 
addition of a methyl group at the fifth position on the cytosine ring primarily in a 
palindromic 5’-CpG-3’ dinucleotide context (30) and occasionally in non-CpG 
dinucleotide context (31-33) (Figure 1.1).  
 The human genome has 56 million CG dinucleotides of which 60 to 80% 
are methylated (34). However, the CpG dinucleotides are underrepresented in 
the genomes of mammals by 5- to 10-fold in comparison to the other 
dinucleotides because of deamination of 5mC to T thus creating TG mismatches 
which can be fixed as C to T transitions (35). Interestingly, unmethylated 
cytosines deaminate nearly four times slower than 5mC to uracil, creating UG 
mismatches which are efficiently removed from the DNA by uracil glycosylases 
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(36). As a result of this preferential deamination the human genome is CG 
dinucleotide deficient.  
 Also, the occurrence of CpG dinucleotides is non-random. While most 
regions of the mammalian genome are CpG poor, repetitive DNA sequences and 
regions called CpG islands harbor CpG dinucleotides nearly at their statistically 
expected levels (37).  
 By definition a CpG island is a stretch of DNA that is on average 1000bp 
long, has a G+C content of at least 50% and has a ratio of observed 
CpG/expected CpG more than 60%. In the non-CpG island regions of the 
genome this ratio is as low as 0.1 to 0.2 (37). In the human genome 50% of all 
genes harbor CpG dinucleotides in their promoters (38) (Figure 1.2).  
 However, for most ubiquitously active genes the CpG dinucleotides in the 
transcription start site (TSS) associated with promoters are constitutively 
unmethylated and gene bodies are heavily methylated (34,39,40). The 
methylation of the gene body occurs perhaps to prevent spurious transcription 
initiation leading to formation of truncated proteins. Also the unmethylated CpG 
dinucleotides may be a defense mechanism to protect the promoters of genes 
from spontaneous mutation because of to 5mC to T transitions.  
 It has been observed that CpG dinucleotides are sometimes methylated in 
a tissue-specific manner but these methylation profiles are not inherited from the 
germ cells (34,41-45). DNA methylation of the promoter often correlates with 
gene repression in a tissue specific manner (34,39,42). As a rule of thumb, the 
CpG islands associated with imprinted genes and genes associated with X 
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chromosome inactivation, and inactivated tumor suppressor genes in 
pathological conditions are almost always silenced by hypermethylation.  
 
1.3 DNA methylation in development 
 Mammalian genomes witness genome-wide epigenetic reprogramming via 
waves of DNA methylation and DNA demethylation at two distinct stages. In mice 
it is first observed in the primordial germ cells (PCGs) around E10.5 to E13.5 and 
then from the newly fertilized egg to the morula stage before preimplantation 
(46). At the time of primordial germ cell maturation into sperm and eggs the 
highly methylated PGCs undergo genomewide demethylation in both male and 
female germ cells, which completes by E13 and E14 (47,48). Remethylation in 
the male PCG occurs at prospermatogonia stage (E15 to E16), in females the 
remethylation occurs in the growing oocyte (47,48). Perhaps this wave of 
demethylation is required to erase and establish imprints according to the sex of 
the germ line. 
 The genes responsible for active DNA demethylation have been a 
controversial issue. Recently in zebrafish embryos a complex of aid, mbd4 and 
the gadd45 proteins was shown to be involved in active DNA demethylation of 
exogenous, methylated plasmids (49). This study confirmed the existence of a 
DNA demethylation complex. Also, it is likely that this and other complexes may 
be involved in epigenetic reprogramming of the methylome during embryonic 
development. Interestingly, a novel class of proteins, the ten-eleven translocation 
(TET), belonging to the class of enzymes methylcytosine dioxygenase have been 
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shown to be involved in epigenetic reprogramming via regulating the 5-
hydroxymethylcytidine (5hmC) content of the genome (50). 
 At fertilization the bulk methylation levels of the sperm are higher than that 
of the egg. The sperm genome is demethylated shortly after fertilization (48), and 
the genome of the newly developing zygote experiences a wave of 
reprogramming. After this second wave of demethylation in mammalian 
development de novo methylation occurs in selective intermediate cell mass 
(ICM) cells at the time of implantation to establish embryonic lineages and cell 
identities (51). At this time the bulk methylation of the developing zygote is 
equivalent to the bulk methylation levels of the sperm. However, how these new 
methylation marks are established in tissue specific genes is not clear. Figure 1.3 
summarizes the dynamics of 5mC content during embryonic development. 
 It is postulated that the second wave of demethylation helps in erasing the 
paternal and maternal methylation signature to set up new methylation marks in 
the genome of the developing embryo that will be distinct from that of the 
parents. In mammals this early wave of embryonic demethylation is mostly 
conserved. However, there are some variations in timing or extent of 
demethylation. Interestingly, it is still not clear if there is a genome-wide paradigm 
for this re-establishment phase although some tissue-specific genes (44,52), and 
pluripotency genes (53) are targets of promoter methylation. Importantly, the 
factors that dictate the new differential methylation patterns, and the recruiters of 




1.4 DNA methylation in a non-CpG dinucleotide context 
 One of the non-CpG methylation marks that has recently been discovered 
is 5-hydroxy methylcytosine or 5hmC within the mammalian neuronal and 
embryonic stem cell genomes (50, 54). This modified base is also called the sixth 
nucleotide and is formed by the conversion of 5mC by the protein ten-eleven 
translocation 1 (TET1), belonging to the class of enzymes methylcytosine 
dioxygenase (50). Figure1.1 shows the structure of the 5-hydroxymethylcytidine. 
 TET1 utilizes 2-oxoglutarate (2OG)- and Fe (II) to oxidize 5mC to 5hmC 
(50). In ES cells TET1 protein associates and colocalises with SIN3A co-
repressor complex (55). However, of 5hmC is not only present at promoters and 
CpG islands (3) but also at enhancers and gene bodies (56). Because 5hmC is 
associated with euchromatic DNA it is thought to be an activating mark (3). 
Interestingly, pre-existing 5mC marks are required for the formation of the 5hmC 
residues (3). This again highlights the importance of 5mC in the mammalian 
genome. Perhaps the occurrence and the genomic distribution of 5mC lay down 
the blueprint for different modifications during this epigenetic reprogramming.  
 In genome wide studies in ES cells 5hmC has been shown to enrich at 
OCT4 and NANOG binding sites (56-58), promoters of genes that harbor both 
repressive H3K27me3 and the activating H3K4me3 histone marks (59) and at 
enhancers bearing activating H3K4me1 and H3K27ac marks (56). Also, it has 
been suggested that 5hmC levels are dynamic during development, its levels first 
increase in murine ES cells and then decrease on differentiation into embryoid 
bodies (4). 5hmC is expressed in the brain and heart of human and murine 
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tissues, suggesting that it may be required in a tissue-specific manner to regulate 
gene expression (4). Other than these two modifications ES cells also harbor 
some cytosine methylation at CpA and CpT sites (31) although the functions of 
these modifications are not clear. 
 The above data suggest that non-CpG methylation may also play a 
number of functions in regulating the chromatin architecture during development 
and disease.  
 
1.5 DNA methylation and cell differentiation 
 All cells of a multicellular organism are similar at the genetic level. 
However, the cells have distinct structures and functions depending upon the 
type of genes they express. The regulation of gene expression in different cell 
types and different tissue types of a multicellular organism is controlled in part by 
DNA methylation.  
 However, one school of thought argues that methylation or de-methylation 
of promoters of genes cannot be the primary effectors of cellular differentiation. 
According to this theory cellular differentiation occurs in both kinds of organisms, 
those that have DNA methylation (vertebrates, fungi and flowering plants) and 
those that show very little evidence of DNA methylation (Caenorhabditis elegans 
Sachharomyces cerevisea and Drosophila melanogaster).  
  Thus it has been hypothesized that, unlike DNA methylation that is a non-
conserved cellular mechanism, differentiation is more likely to be controlled by 
biological processes that are conserved through evolution. However, mounting 
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evidence points in favor of DNA methylation regulating differentiation.  Studies 
indicate that genes have differential methylation in different tissue types during 
embryonic development, suggesting that DNA methylation indeed may be 
required during differentiation (60-63). 
 
1.6 Mammalian DNA methyltransferases 
 Mammals harbor three catalytically active DNA methyltransferase proteins 
called DNMT1, DNMT3A and DNMT3B. The third member of the DNMT3 family 
is DNMT3L that is devoid of DNA methyltransferase catalytic activity. The generic 
DNA methyltransferase protein consists of two main parts, a multidomain N-
terminal regulatory region that varies in size depending upon the DNMT and a 
highly conserved C-terminal catalytic domain. Figure 1.4 shows the different 
domains of the murine DNA methyltransferases.  
 The highly divergent N-terminus of the protein mediates interactions with 
DNA, chromatin and other proteins. This region of the protein also helps in 
nuclear localization. The C-terminal part of the DNMTs is smaller but highly 
conserved across species. It has the 10 amino acid motif that serves as a 
signature for all DNA methyltransferases (79). The catalytic domains have the 
AdoMet-dependent MTase fold and this region helps both in cofactor binding and 
catalysis. The transcription repression domain (TRD) is non conserved among 






1.6.1 Enzyme classification 
 Based on their structure the DNA methyltransferases are divided into two 
main classes: the DNMT1 and DNMT3 family. Based on their function the DNA 
methyltransferases can be categorized into two main classes, the maintenance 
and the de novo methyltransferases. The maintenance class prefers 
hemimethylated DNA as substrate and helps in maintaining the methylation 
status in dividing cells in every replication cycle. DNMT1 in mammals is deemed 
the maintenance methyltransferase. It has 10- to 50-fold higher preference for 
hemimethylated DNA over unmethylated DNA as a substrate in vitro (81, 82).  
 De novo methyltransferases are the ones that methylate CpG 
dinucleotides at completely unmethylated substrates. DNMT3A and DNMT3B are 
the de novo DNMTs. It has been shown that DNMT3A and DNMT3B are the 
enzymes that hypermethylate and silence viral repeat sequences as well (83, 
84). 
 However, the distinctions based on substrate preference are not absolute. 
DNMT1’s specific activity on unmethylated substrates is much greater than that 
of DNMT3A and DNMT3B. Importantly, overexpression of Dnmt1 in mice leads to 
aberrantly methylated regions of imprinted loci suggesting that Dnmt1 in this 
scenario can act as a de novo DNA methyltransferase. This distinction also fails 
in the case of DNMT1 deficient cell lines where in the absence of DNMT1 
methylation levels in the genome are maintained. This suggests that other 





 Dnmt1 was the first mammalian DNA methyltransferase gene cloned (87) 
and characterized biochemically. The preference of Dnmt1 for hemimethylated 
DNA can be attributed to its localization at the replication fork during the S phase  
(88, 89). Figure 1.4 shows the domain structure of Dnmt1. DNMT1 is a large 
protein of 1620 amino acids in mouse and 1616 amino acids in humans. The N- 
and C-termini are connected through lysine-glycine repeats. The N-terminal 
regulatory region has various domains that that may help in mediating its 
functions.  
 The main N-terminal regulatory domains of DNMT1 are 1) DMAP1- (DNA 
methyltransferase associated protein 1) interaction domain; 2) PBD domain- 
PCNA (proliferating cell nuclear antigen) binding domain; 3) Three independent 
NLS sequences; 4) TS targeting sequence domain; 5) CXXC containing zinc-
finger-binding domain between the PCNA-binding and the BAH regions. Dnmt1 
has eight cysteine residues in two CXXCXXCXXC motifs. 6) BAH 1 and 2 
domains- (Bromo-adjacent homology) and 7) KG (series of lysine and glycine 
residues) linker localized between N- and C- terminal part of the enzyme.  
 The C-terminal catalytic domain of Dnmt1 requires the other motifs to 
perform its function both in vitro and in vivo (90). The expression of mammalian 
DNMT1 protein is affected by a number of factors both in disease and 
development. Some of these regulatory controls are mediated by miR-148 (91-
93), miR-152 (91) and miR-126 (94). In addition posttranslational modifications 
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like phosphorylation, methylation, acetylation, ubiquitination, and sumoylation 
affect the stability, activity and turnover of the DNMT1 protein (95). 
 
1.6.3 DNMT3 
 The mammalian DNMT3 family has three main members: DNMT3A, 
DNMT3B and DNMT3L. DNMT3A and DNMT3B establish the methylation 
patterns required for early development. These enzymes are also required to 
establish methylation patterns in the primordial germ cells. DNMT3L is 
catalytically inactive and functions as a cofactor for DNMT3A and DNMT3B. Its 
function is required in germ cells.  
 Dnmt3a and Dnmt3b are de novo DNA methyltransferases, however in 
vitro they do not show significant preference for hemimethylated or unmethylated 
DNA as substrate (84, 96). Interestingly, although DNMT3 family members are 
primarily considered as de novo DNA methyltransferases, they have been shown 
to play a role in maintaining methylation at heterochromatic DNA sequences (97). 
 Although there may be some functional over lap in the functions of Dnmt1, 
Dnmt3a and Dnmt3b they have distinct tissue-specific functions, too. ICF 
syndrome is caused by mutations in the DNMT3B gene and DNMT1 or DNMT3A 
do not complement for the reduced activity of DNMT3B. The fact that 
hypomorphic DNMT3B is sufficient to cause this disease suggests that DNA 
methyltransferases may have discrete functions during development. 
 Like Dnmt1, the Dnmt3 family possesses a conserved C-terminal catalytic 
domain containing C5 DNA methyltransferase motifs. The N-terminal regulatory 
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domain of Dnmt3a and Dnmt3b are unrelated. The N-terminal has the 1) 
Cysteine rich ADD (ATRX-DNMT3-DNMT3L) domain also called the PHD (plant 
homeodomain) domain; 2) And a PWWP domain that is absent in Dnmt3l. The 
Dnmt3l protein also lacks the methyltransferase motifs IX and X and other 
catalytic residues that are found in the other DNA methyltransferases. The 
interacting partners and the functions of these domains are listed in Table 1.1. 
 There are many isoforms of Dnmt3a and Dnmt3b produced by alternative 
splicing. These isoforms differ in sizes and expression patterns however factors 
controlling this alternative splicing are not known. Dnmt3a produces two isoforms 
1) Dnmt3A and 2) Dnmt3A2, which is shorter. The two proteins have similar 
methyltransferase activity but vary in their localization during development. 
DNMT3A has ubiquitous expression while, DNMT3A2 has a very specific 
expression pattern. DNMT3A2 is restricted to the ES cells and germ cells, 
suggesting that these two isoforms may have different tissue-specific functions in 
embryonic development (98). Like DNMT1, DNMT3 proteins are also regulated 
both at posttranscriptional and posttranslational levels (95). 
 Both in mice and in humans there are six isoforms of DNMT3B 
(96,121,122) that arise from alternative splicing and retain different portions of 
the N and C termini. Based on the retention of the active site in the C-terminus 
and in vitro activities, DNMT3B1 and DNMT3B2 proteins are catalytically active. 
DNMT3B3 and DNMT3B6 have been shown to be catalytically active in vitro 
(123) and in vivo (124). So far it is not known whether the other DNMT3B 
isoforms are active.  
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 Because the DNA methyltransferase 3 isoforms are conserved in 
evolution it is likely that they have undiscovered functions, perhaps as regulators 
of the other catalytically active DNMT3Bs, or as modulators of the activity of 
other chromatin modifying proteins. It will be interesting to elucidate the 
molecular functions of the splice variants of these DNA methyltransferases in 
embryonic development in various model systems. 
 Complete ablation of Dnmt1, Dnmt3a, Dnmt3b, and Dnmt3l confers 
varying defects in embryonic development. (83,125-127). These defects have 
been summarized in Table 1.2. Although data from knock-out studies underscore 
the importance of these DNA methyltransferases during embryonic development, 
the early lethality of affected embryos renders them unsuitable to study the 
effects of these enzymes in later tissue-specific developmental programs.  
 
1.7 DNA methylation in disease 
 Various human diseases have directly been related to defects associated 
with the DNA methylation machinery. 
 
1.7.1 ICF syndrome 
 Type-1 ICF syndrome (Immunodeficiency Centromere instability and 
Facial anomalies) is the only disease that is known to occur due to homozygous 
or compound heterozygous mutations in a DNA methyltransferase gene. The 
majority of mutations in DNMT3B are missense mutations, others include 
nonsense and splice-site mutations (64). ICF is a rare autosomal recessive 
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disorder affecting around 50 patients worldwide (65, 66). However, because the 
clinical symptoms are diverse and depending on the availability of proper health 
care the incidence may be poorly reported. 
 The ICF patients exhibit a 7% decrease in global 5mC levels (67). Based 
on mutations in DNMT3B, the ICF syndrome is divided into two classes. In the 
Type 1 ICF syndrome (65% of ICF patients) there are biallelic missense 
mutations in the C terminal catalytic domain of DNMT3B (28). Another study 
shows two related patients that exhibit mutations outside the catalytic domain 
primarily in the PWWP domain of DNMT3B (68).  
 In Type 1 ICF cases, patients suffer from decreased levels of humoral 
immunity despite the presence of B cells. The early stages of lymphocyte 
differentiation are not affected but there may be defects in lymphocyte maturation 
or activation (69). These patients exhibit a broad spectrum of facial anomalies 
that include hypertelorism (widely spaced eyes), micrognathia (small jaws), low-
set ears, epicanthal folds and macroglossia (protrusion or enlargement of 
tongue), mental retardation, respiratory and intestinal tract infections and low 
birth weight (28).  
 In cytogenetic analyses, tandemly repeating, noncoding DNA regions like 
satellite 2 of the long arms of chromosome 1 and 16, and satellite 3 DNA in the 
long arms of chromosome 9, nonsatellite repeat NBL2 on acrocentric 
chromosomes and D4Z4 in subtelomeric regions of chromosomes 4 and 10 are 
demethylated in all tissues but chromosomal instability is associated only with 
lymphocytes (67, 70). In lymphocytes the juxtacentromeric heterochromatin of 
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chromosome 1, 9 and 16 is elongated leading to formation of multiradiate 
chromosomes (28). The hypomethylation of satellite 2 and 3 regions leads to 
centromeric instability (70).  
 The peripheral blood of ICF patients has only naïve B cells with defective 
negative selection and terminal differentiation (71). The chromosomes 1, 9 and 
16 show branching after mitogen PHA (phytohemeagglutination) stimulation of 
lymphocytes.  
 However, in Type 2 ICF (nearly 40% of ICF cases), patients do not exhibit 
mutations in DNMT3B and these patients show the same phenotypes as the 
patients with this mutation. Type 2 patients also show hypomethylation of 
tandemly repeated DNA regions on the centromere called alpha satellites, in 
addition to hypomethylation of DNA regions seen in ICF type 1 (72, 73). 
Recently, type 2 ICF patients with mutations in a zinc-finger- and BTB (bric-a-
bric, tramtrack, broad complex)-domain-containing 24 (ZBTB24) gene have been 
identified (74). Importantly, because of the lack of large patient sample sizes and 
smaller life spans of the affected patients, animal models that mimic the disease 
are required to dissect the molecular mechanism associated with the disease. 
 
1.7.2 Imprinting defects 
 Genomic imprinting refers to the epigenetic mechanism that maintains 
gene repression in parental germ lines so that the progeny inherits monoallelic 
gene expression in parent-of-origin specific manner. There are a number of 
diseases that are associated with deregulated imprinting mechanisms; two of 
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them are Beckwith-Wiedemann syndrome (BWS) (75) and Prader-
Willi/Angelman syndrome (PWS/AS) (76).  
 In BWS patients there is biallelc expression of IGF2, which in normal 
conditions is only expressed from the maternal allele. In PWS and AS there are 
deletions on chromosome 15 that affect the paternal allele in PWS patients and 
the maternal allele in AS patients. In some AS cases mutations have been 
mapped to UBE3A gene that is imprinted in a tissue-specific manner (77).  
 The imprinted genes have only one functional allele. If the imprinted gene 
has a tumor suppressor activity, then loss of heterozygosity (LOH) can cause 
cancer. Interestingly, a number of defects in imprinted genes are related to 
cancer predisposition due to LOH. These include neuroblastoma, acute 
myelogenous leukemia, rhabdomyosarcoma, sporadic osteosarcoma and Wilms’ 
tumor (78).  
 
1.7.3 Cancer 
 In cancer cells the global methylation picture is quite different from that in 
normal cells. At global levels the genomes of cancer cells are hypomethylated 
where as there is region specific hypermethylation leading to aberrant silencing 
of tumor suppressor genes and genes involved in all cellular pathways. There is 
little explanation for this paradoxical phenomenon. In a number of cancers this 
hypermethylation (29) is used as a prognostic marker.          
 However, it is still not clear why some genes are hypermethylated in 
certain forms of cancer while others are not. It is believed that DNA 
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hypomethylation leads to chromosomal instability that may lead to further 
mutations in genes thus indirectly causing cancer. In many cancers there is 
aberrant methylation of differentially methylated regions (DMRs) (15). One may 
speculate that insight into the interacting partners of the DNMTS may shed light 
into the aberrant recruitment of the DNMTS to different genetic loci in 
pathological conditions. 
 
1.8 Conditional knockout models 
 To understand the involvement of DNA methyltransferases in tissue-
specific methylation patterns different DNA methyltransferases have been 
conditionally knocked out alone or in combination. Also, ICF syndrome has been  
modeled in mice to dissect the molecular involvement of Dnmt3b in disease 
progression and pathophysiology. 
 
1.8.1 ICF Syndrome 
 To model the ICF syndrome transgenic mouse lines were created carrying 
two missense mutations A609T and D823G that lead to partial loss of function of 
Dnmt3b (131). The missense mutant mice developed to term but most of the ICF 
neonatal mice died one day after birth. Some survived to adulthood. The mice 
that survived recapitulated only some aspects of the human disease. They 
displayed facial dysmorphism and low weight at birth. Unlike agamma-
globulinemia that is observed in most patients these mice exhibit defects in the T 
cell lineage.  
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 After birth, the numbers of thymocytes were reduced due to apoptosis in 
the thymus. This suggested that in mice Dnmt3b activity is essential for the 
survival of thymic T cells and not mature B cell populations. At the cytogenetic 
level the mice display hypomethylation of centromeric minor satellite DNA and 
juxtacentromeric major satellite DNA. Perhaps, differences in cytogenetics of 
DNMT3B deficient humans and mice arise due to differences in chromosomal 
organizations of these two organisms. In summary Dnmt3b deficient mice show 
more extensive DNA hypomethylation and the kind of immunological dysfunction 
is different from humans. 
 A challenge with modeling human diseases in animals is that most 
disease models only phenocopy certain aspects of the disease. Moreover, the 
extent of similarities may vary and some phenotyes may be completely model 
specific. However, to circumvent this caveat cumulative data from multiple model 
systems may be useful in generating a better understanding of a human disease. 
Importantly, because of the rare numbers of available ICF patient samples it is 
imperative to develop cost effective model systems that will recapitulate different 
aspects of the disease. 
 
1.8.2 Conditional knockout of Dnmt1, Dnmt3a  
and Dnmt3b in HSCs 
 The hematopoietic system is a robust model system to study epigenetic 
decisions that regulate cell fate commitments (25, 132, 133). In a recent study 
Feinberg and colleagues mapped the methylation status of 4.6 million CpG sites 
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of murine hematopoietic progenitors (132). They identified differentially 
methylated genes of noncommitted and lineage-committed progenitors. This 
study identified lymphoid and myeloid specific genes like Lck, Mpo, Cxxcr4 and 
Gadd45a that are regulated by promoter methylation in various stages of 
progenitor cell development. 
 Also, the authors further corroborated earlier findings which suggested 
that progression of uncommitted progenitors to the myeloid lineage requires less 
global DNA methylation than that needed for the generation of lymphoid lineage 
progenitors (134).  Feinberg et al. (132) could faithfully recapitulate this 
observation in vitro by pharmacologically modulating CpG methylation. 
Treatment of bi-potential progenitors with 5-aza-2’-deoxycytidine increased 
myeloid progenitors at the cost of lymphoid progenitor cells. However, since 5-
aza-2’ -deoxycytidine is a nonspecific nucleoside inhibitor of the DNMTs (135), it 
cannot be distinguished whether this myelo-lymphoid lineage commitment is 
regulated discretely by Dnmt1, Dnmt3a or Dnmt3b or by a combination of these 
enzymes.  
 Interestingly, Feinberg et al. (132) also showed that at various stages of 
lineage commitment, the levels of Dnmt3b are dynamic. They are highest in 
multipotent progenitors. The levels of Dnmt3b first decrease, then again increase 
in later stages of lymphoid progenitors. In contrast, the myeloid progenitors show 
a progressive decrease of Dnmt3b transcript levels as they progress towards 
lineage restriction. Interestingly, this dynamic expression profile of Dnmt3b is 
itself regulated by promoter methylation. These epigenetically induced variations 
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in the levels of Dnmt3b during different steps of hematopoietic differentiation 
suggests that Dnmt3b may be required in a graded manner to maintain the 
chromatin states of hematopoietic genes involved in lineage commitment of 
blood cells.  
 However, in this study the authors did not investigate the levels of Dnmt1, 
Dnmt3a and Dnmt3b in terminally differentiated hematopoietic cells. Also, the 
question whether DNA methyltransferase function is required for the formation of 
terminally differentiated populations of blood cells has not been addressed to 
date. Answers to these questions are particularly relevant in the context of 
various hematological disease conditions that exhibit both mutations and 
transcriptional deregulation of the DNMT genes (28,136-138). 
 Different studies have implicated the involvement of the DNA 
methyltransferases in normal development of various hematopoietic cells. In a 
recent finding it was reported that during lymphocyte activation Dnmt3a 
expression is induced by T cell receptor stimulation. However, the protein levels 
of DNMT3A are reduced by costimulation (139). The exact functional 
consequences of this stage-specific transcriptional regulation of Dnmt3a in these 
two lymphocyte activation steps are not known.  These authors also investigated 
the functions of DNMT3A using Dnmt3a knockout mice as a model system. 
Interestingly, they did not observe any defects in the maturation of T cells lacking 
DNMT3A. 
 Contrary to the above findings, other studies provide strong evidence of 
regulation of T cell differentiation by both Dnmt3a and Dnmt3b. Promoter 
  
21 
methylation is implicated in regulating the expression of Foxp3, a gene required 
for CD4+/CD25+ regulatory T cells, a cell type that plays a role in maintenance of 
immunological tolerance (140-143) in the periphery. 
 A SUMO E3 ligase PIAS1, binds to the Foxp3 promoter to recruit 
DNMT3A and DNMT3B that confer promoter methylation. This promoter 
methylation negatively regulates the expression of Foxp3 to prevent T cell 
differentiation into regulatory T cells (25). Interestingly, it has been reported that 
the demethylated and not the methylated regions of the Foxp3 locus in regulatory 
T cells are bound by the ETS1 protein to regulate the expression of Foxp3 (144). 
In vitro experiments have identified physical interaction between the de novo 
DNA methyltransferases DNMT3A and DNMT3B and the ETS transcription factor 
PU.1, a key regulator of myeloid and B cell lineage development (103). Also, 
microRNA 29b (miR-29b) has been shown to regulate the expression of DNMT1, 
DNMT3A and DNMT3B in acute myeloid leukemia cells (145).  
 To further characterize hematopoietic functions of the DNMTs, 
investigators have employed tissue-specific loss-of-function approaches 
specifically targeting the hematopoietic compartment of model systems. 
Functional knockout of Dnmt1 created by inducing the removal of the catalytic 
domain of DNMT1 in the HSCs is incompatible with survival (134). These mice 
die due to the inability of HSCs and the progenitors to differentiate and by the 
induction of apoptosis. The Dnmt1-/chip mice are produced on combining the 
hypomorphic Dnmt1 allele with the Dnmt1 null allele. It was observed that these 
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Dnmt1-/chip mice showed a severe reduction in the Lymphoid Primed 
Multipotential Progenitors and a 2.7-fold enrichment of long-term HSCs.   
 The Dnmt1-/chip mice exhibit a reduction in common lymphoid progenitors 
and T cell progenitors. Interestingly, the Dnmt1-/chip mice do not exhibit any 
changes in the frequencies of differentiated myeloid and erythroid cells.  There 
are two possible explanations for this observation. First, DNA methylation may 
not be required for the formation of mature erythroid and myeloid cell 
populations. Second, instead of Dnmt1, Dnmt3a and/or Dnmt3b that are still 
expressed in the Dnmt1-/chip mice may regulate the differentiation of the myeloid 
and erythroid lineages into mature cells. Furthermore, hematopoietic progenitors 
in the bone marrow of the Dnmt1-/chip mice lack the expression of Pax5, an early 
B cell marker suggesting that decreasing the levels of Dnmt1 indirectly silences 
Pax5 expression. The authors also show the transcriptional upregulation and 
promoter demethylation of lineage-specific genes like Gata1 and Cd48 as a 
consequence of reduction in the levels of Dnmt1 in the HSCs of Dnmt1-/chip mice.  
 In contrast to the above report, ablation of Dnmt1 in the hematopoietic 
compartment, obtained by crossing Dnmt1fl/fl with interferon-inducible Mx-Cre 
transgenic mice, does not exhibit hematopoietic defects in terminally 
differentiated blood and progenitor cell types (146). This observation again 
alludes to the idea that Dnmt1 may not be required for terminal differentiation of 
different lineages in hematopoiesis and that Dnmt3a and/or Dnmt3b may be 
involved instead.  Based on cell transplantation studies and competitive 
transplantation assays these authors concluded that Dnmt1 is not only required 
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for self-renewal and differentiation of the HSC cells but also for differentiation into 
mature myeloid cells only. These conclusions were primarily based on the 
observation that in competitive repopulation assays, unlike B and T cells, only the 
myeloid cells were drastically reduced. However, these defects could have arisen 
because of failure of competitive engraftments. Also, differences in the methods 
used for generating the transgenic lines in the studies described above may be 
responsible for the different outcomes. 
 Thus based on the data discussed above it is difficult to conclude whether 
Dnmt1 is required solely for the generation of terminally differentiated cells of 
myeloid lineage (146) or  for the lymphoid lineage (134) and also that Dnmt3 
family genes may play an unrecognized role in regulating formation of terminally 
differentiated hematopoietic cells. Further studies aimed at elucidating the 
functions of DNA methyltransferases are required to reconcile these observations 
and for dissecting the contributions of different DNMTs in various steps of 
hematopoiesis. 
 Because hypomorphic DNMT3B is involved in hematopoietic defects 
caused by ICF syndrome, the contribution of Dnmt3a and Dnmt3b was 
elucidated in hematopoiesis (147). In mice Dnmt1, Dnmt3a, Dnmt3a2 and 
Dnmt3b are expressed at different levels in various populations of the 
hematopoietic cell types. Dnmt3a, Dnmt3a2 and Dnmt3b are robustly expressed 
in B and T lymphoid lineages whereas their expression is very weak in 
neutrophil/macrophage and erythroid lineages. The CD34-/low, c-Kit+, Sca-1+, 
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lineage marker- (CD34- KSL) cells, a population enriched in hematopoietic stem 
cells has robust expression of all Dnmt1, Dnmt3a, Dnmt3a2 and Dnmt3b (147).  
 Myeloid and lymphoid differentiation potential from HSCs were 
uncompromised when measured by in vitro colony forming assays, and by in vivo 
transplantation assays in mice lacking Dnmt3a, Dnmt3b or both in their 
hematopoietic compartment. However, when these HSCs were challenged with 
long-term reconstitution by transplantation assays they lost their reconstitution 
potential. The authors concluded that Dnmt3a and Dnmt3b are required for self-
renewal but not for differentiation in hematopoietic stem cell (147).  
 Interestingly, different studies have suggested two different ideas 
regarding the contribution of Dnmt1 during hematopoiesis. The first one claims 
that Dnmt1 is solely required for the terminal differentiation of the myeloid lineage 
(134) and the second one suggests that it is only required for the generation of 
the terminally differentiated cells of the lymphoid lineage (146). However, further 
studies are required to address the requirement of the DNA methyltransferases 
during hematopoiesis.  
 DNA methylation has also been shown to play a role in the development 
of other organ systems. To study the contributions of DNA methylation in the 
central nervous system DNA methyltransferases have also been knocked out 






1.9. Major unresolved questions 
 The data discussed above point out some unanswered questions in the 
field of DNA methylation and its impact on development and disease. 
1. Do the different isoforms of DNMT3A and DNMT3B families have tissue-
specific functions? 
2. Do the different isoforms of DNMT3A and DNMT3B regulate each other as 
cofactors? 
3. What are the functions of various DNMT3A and DNMT3B isoforms in 
imprinting and sex determination? 
2. What are the contributions of the different de novo DNA methyltransferases in 
hematopoietic development? 
3. What are the genetic targets of the different DNA methyltransferases? 
4. What are the signaling pathways that are down stream effectors and 
regulators of DNA methyltransferases? 
5. Can we establish tractable model systems for ICF syndrome? 
6. Can we develop tractable model systems to screen for specific drugs against 
the different DNA methyltransferases? 
 Answers to the above questions are pertinent in understanding the 
contributions of different DNA methyltransferases in embryonic development and 
disease conditions. Also, they are essential for developing better therapeutics 
against the diseases discussed. To investigate the above queries we chose 




1.10 Zebrafish as a model system 
  Danio rerio (zebrafish) is a popular model system for biological research. 
Briefly, zebrafish are easy and economical to maintain. They have short 
generation times. The females are highly prolific in producing eggs. Embryonic 
developmental patterns are similar to mammals (151, 152) and development is 
external and rapid thus providing easy access to clinical and genetic 
manipulations. Because the developing embryos are transparent, developmental 
processes can easily be monitored using standard techniques. 
 Notably, zebrafish are highly amenable to genetic (153) and 
pharmacological (154, 155) manipulations, this makes them tractable tools to 
study genetics and epigenetics (156). Lastly, the fact that the zebrafish genome 
is being sequenced renders them an attractive model system to dissect the roles 
of the evolutionary conserved DNA methyltransferases (157) in development (49, 
60, 61, 158-162) and disease (163-166).  
 Based on sequence similarity, zebrafish harbor orthologs of all the 
mammalian DNA methyltransferases (167). The zebrafish DNA 
methyltransferase proteins bear resemblance both to the mammalian 
maintenance DNA methyltransferase Dnmt1 (168,169) and the de novo DNA 
methyltransferases Dnmt3a and Dnmt3b (122).  
 
1.11 DNA methyltransferases in zebrafish 
 Zebrafish harbor all known orthologs of mammalian DNA 
methyltransferases (167). Figure 1.5 shows the structures of the zebrafish DNA 
  
27 
methyltransferases. Zebrafish have seven DNA methyltransferase genes namely 
dnmt1, dnmt3, dnmt4, dnmt5, dnmt6, dnmt7 and dnmt8. Based on sequence 
similarity and functional analyses it has been suggested that dnmt1 is the 
maintenance DNA methyltransferase. Also, dnmt3, 4, 5, 6, 7, and 8 are 
homologs of mammalian Dnmt3a and Dnmt3b. Interestingly, both dnmt1 mutant 
(158) and morphant (60) embryos largely phenocopy each other. Table 1.3 
summarizes the zebrafish DNA methyltransferase morphant and mutant 
phenotypes.  
 Interestingly, zebrafish also harbor proteins that can actively demethylate 
exogenous methylated plasmids (49, 60) suggesting that zebrafish might utilize 
both DNA methylation and DNA demethylation to guide normal development. 
Notably, the lack of a protein that bears sequence similarity to Dnmt3l in 
zebrafish has lead to the idea that zebrafish do not have imprinting and provide a 
simple model system to study the contributions of different DNA 
methyltransferases in tissue-specific development.   
 Data from our lab suggests that dnmt1 and dnmt3 in zebrafish harbor both 
overlapping and discrete tissue-specific functions (60, 61). Based on the data 
discussed above, I hypothesize that DNA methyltransferase 4, 5, 6, 7 and 8 in 
zebrafish guide terminal differentiation of both common as well as discrete 








 While involvement of DNA methylation in regulating tissue-specific 
terminal differentiation has been a contentious issue. Recent data from our lab 
and others have supported this view.  The data presented in this thesis 
characterize the phenotypic consequences of morpholino knock down of dnmt4, 
dnmt5, dnmt6, dnmt7, and dnmt8. These bear sequence similarity to the 
mammalian Dnmt3a and Dnmt3b family. Chapter 2 highlights the 
characterization of expression pattern, antisense morpholinos and impact of 
knock down on global methylation status of dnmt4, dnmt5, dnmt6, dnmt7, and 
dnmt8. Chapter 3 characterizes the details of molecular defects observed in 
dnmt4 morphants. This chapter also delineates the requirement of dnmt4 in 
zebrafish hematopoiesis. Also, in this chapter we show epistatic relationship 
between retinoic acid signaling and dnmt4. In Chapter 4 I have shown epistatic 
relationship between adenomatous polyposis coli (apc) and dnmt4.  
In Chapter 5 I have summarized the main findings of this work and its 
implications. Appendix A shows the characterization of expression patterns, 
morpholinos, and morphological defects of methylated DNA binding proteins, a 
class of proteins that recognize methylated CpG dinucleotides. I have shown 
data for mbd1, md3a and mbd3b in zebrafish. Appendix B shows the effects of 











Figure 1.1. The two main modified nucleotides present in DNA of mammals. 
Cytosine on deoxycytidine (present in CpG dinucleotide context) are modified to 
5-methyldeoxycytidine by DNA methyltransferases that use s-
adenosylmethionine (SAM) as a cofactor. The 5mC is often called the 5th 
nucleotide. 5-methyldeoxycytidine can further be modified into 5-
hydroxymethyldeoxycytidine by TET proteins. The 5-hydroxymethylcytosine 
(5hmC) is referred to as the 6th nucleotide. These two modified nucleotides have 








Figure 1.2. The genomic distribution of CpG dinucleotides. (A) In the 
genomes of higher eukaryotes the distribution of CpG dinucleotides is non 
random. Regions where CpG dinucleotides are expressed at their statistically 
expected frequency are called CpG islands. The CpG islands are present in the 
transcriptional start sites (TSS), intragenic regions and intergenic regions. (B) 
The pie chart shows the distribution of CpG islands as a percentage in the 
human genome. 50% of the CpG dinucleotides are present in the start sites 
(TSS), and 25% each in the intragenic regions and intergenic regions. The total 
number of genes analyzed was 25,495. The data in (B) is adapted from 






Figure 1.3. Dynamic profiles of bulk methylation in development 
The dynamic profiles of bulk levels of 5mC in the genome of the developing 
embryo and in the primordial germ cells. The global levels of bulk methylation are 
higher in sperm in comparison to the egg. At fertilization the bulk methylation 
levels of the zygote first decrease, suggesting the occurrence of active DNA 
demethylation and then are regained in later stages of embryonic development 
suggesting that this remethylation may occur in a tissue specific manner to 
confer cell identity and terminal differentiation. However, it is not known which of 
the DNA methyltransferases target the different genetic loci during this tissue 
specific remethylation phase. This figure is adapted from Heby et al., 1995, 








Figure 1.4. Structure of the mammalian DNA methyltransferases. The 
schematic of different DNA methyltransferases in mammals and their domain 
structures. DNMT1 is the primary maintenance DNA methyltransferase and 
DNMT3A, DNMT3B and DNMT3L represent the main de novo members. The 
DNA methyltransferases harbor a highly conserved C-terminal catalytic domain 
and a divergent N-terminal regulatory domain. Perhaps the N-terminus may help 









Figure 1.5. Diagram of the DNA methyltransferases in the zebrafish. 
Zebrafish harbor both the maintenance and the de novo DNA methyltransferases 
in their genome. They have a conserved C-terminal catalytic domain and a 
divergent N-terminal region. The different domains in the N-terminal help in 
protein-protein interactions and may help in targeting the proteins to their genetic 
loci. We hypothesize that different zebrafish DNA methyltransferases may be 
targeted to different tissues during the re-methylation phase during embryonic 




































DMAP1 (102) PML-RAR (103) DNMT3L (104) 
HDAC2 (102) MYC (105) SUMO-1 (106) 
PCNA (107) RP58 (100) UBC9 (106) 
Rb (108) SUV39H1 (109) DNMT3A (104) 
E2F1 (110) HP1 (109)   
MECP2 (111) PIAS1 (112) DNMT3L 
 
 
DNMT3A (97) UBC9 (112) HDAC1 (113) 
DNMT3B (97) PIASxa (112) DNMT3A (104) 
SUV39H1 (109) DNMT3L (104) DNMT3B (104) 
SET7/9  (114) PU.1 (103)   
G9A (115) SETDB1 (116)   
EZH2  (117) EZH2 (117)   
UHFR1 (118) MBD3 (119)   
PML-RAR (120) BRG1 (119)   
HP1 (109)  
 






















Dnmt1-/-  (125) 
 
- Embryonic lethality (E8.5) 
- Genome wide hypomethylation 
- Loss of imprinting 
 
- YES 
- Main maintenance 
DNMT 





Dnmt3a-/-  (83) 
- Post natal lethality (4 weeks) 
- Loss of de novo methylation 




- de novo activity,  





Dnmt3b-/-  (83) 
- Developmental arrest (E14.5-
E18.5) 
- Loss of de novo methylation 
- Mild neural tube defects 
- Demethylation of minor satellite 
repeat sequences 
 
- YES  
- de novo activity;  
- some maintenance 
activity 







- Viable; males are sterile 
(spermatogenic defects) 
- Females have no viable progeny 
- Loss of maternal and paternal 
imprints 
- NO 
- Cofactor of 
DNMT3A  
(enhances its de 

































Loss of global methylation, curled tails, 
pericardial edema, defects in jaws, intestine, 
retina, exocrine pancreas (60, 158) 
 
dnmt3 No Yes Small brains, defective pharyngeal arch 
formation, defective retinal neural epithelial 
differentiation (61) 
 
dnmt4 No Yes No (167) 
dnmt5 No Yes No (167) 
dnmt6 No Yes No (167) 
dnmt7 No Yes No (167) 
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 CHARACTERIZING DE NOVO DNA METHYLTRANSFERASES  
IN ZEBRAFISH  
 
2.1 Introduction 
           Danio rerio or zebrafish is a widely used model system to study 
development (1, 2) and disease (3, 4). Because murine knockout models of 
critical genes are embryonic lethal they are not useful in studying later 
differentiation programs. Zebrafish offers an evolutionary conserved, cost 
effective, prolific and tractable model system to study contributions of genes in 
normal development and diseases. Large-scale mutagenesis screens in 
zebrafish have identified mutants that phenocopy human diseases thus 
consolidating the usefulness of this model system in disease related research. 
          Also, injection of antisense morpholinos leads to formation of hypomorphic 
zebrafish embryos that have subtle developmental defects in comparison to the 
control embryos. The morpholino knockdown can also lead to a wide range of 
phenotypic and molecular defects. However, specific and nonspecific defects of 
morpholino induced knockdown can be distinguished using widely acceptable 
criteria. These amenable properties of zebrafish circumvent the problems of 




          In zebrafish a total of eight genes that bear sequence homology to 
eukaryotic DNA methyltransferases have been described. These are dnmt1, 
dnmt2, dnmt3, dnmt4, dnmt5, dnmt6, dnmt7 and dnmt8 (Figures 1.5 and 2.7) (5). 
However, unlike mammals which possess three distinct DNMT3 family members 
zebrafish harbors six proteins which resemble in sequence either the mammalian 
DNMT3A or DNMT3B (5). Importantly, of the six DNA methyltransferases that 
bear sequence homology to mammalian DNA methyltransferases there is none 
that resembles DNMT3L. 
      Interestingly, both the mouse and human genomes harbor six isoforms of 
DNMT3B that arise due to alternative splicing (6-8). Given this conservation it is 
possible that these isoforms might have specific biological functions. However, 
this possibility has not been investigated although there is evidence that some of 
these splice variants are enzymatically active (9, 10) and are deregulated in 
certain cancers (11, 12). 
          The six members of the Dnmt3 family in zebrafish namely dnmt3, dnmt4, 
dnmt5, dnmt6, dnmt7 and dnmt8 contain a conserved C-terminal catalytic 
domain and an N-terminal regulatory domain that harbor the characteristic 
PWWP (pro-try-trp-pro) and ADD (ATRX-DNMT3-DNMT3L) motifs (Figures 1.4 
and 2.7). 
          Zebrafish dnmt6 and dnmt8 are orthologous to DNMT3A. The sequence 
identity between dnmt6 and dnmt8 is significant with 77% over all identity and 
89% identity in their catalytic domains (13).  However, it is still not clear whether 




functions during development.  
          Because of the differences in the N-terminal regulatory domains it is 
conceivable that these two genes in zebrafish may have distinct embryonic 
functions. Moreover, the two isoforms of the mammalian DNMT3A (DNMT3A and 
DNMT3A2) have distinct expression patterns.  
          DNMT3A is ubiquitously expressed in all tissues and DNMT3A2 is 
expressed in embryonic stem cells, germ cells, and embryonal carcinoma cells. 
While it is not expressed in adult tissues, but some expression is observed in 
spleen and thymus (14). Zebrafish is an amenable model system to investigate 
the tissue-specific functions of homologs of DNMT3A and DNMT3A2 in 
development. 
          Zebrafish genes dnmt3, dnmt4, dnmt5, and dnmt7 also bear sequence 
homology to the mammalian DNMT3 proteins (5). Dnmt4 exhibits 68% amino 
acid sequence identity with the mouse DNMT3B (13). Importantly, mutations in 
the human DNMT3B leads to immunodeficiency, centromere instability and facial 
anomalies (ICF) syndrome (15). However, whether dnmt4 regulates immune 
functions like human DNMT3B and is involved in hematopoietic programs is still 
not known (5).  
          The remaining members dnmt3, dnmt5, and dnmt7 are fish-specific 
DNMT3 family members and their sequence does not suggest higher similarity to 
either DNMT3A or DNMT3B (13). Zebrafish dnmt3, dnmt4, and dnmt5 are 
present in the same gene cluster (16), but it is still not known if they have similar 




          The recent discovery of an active DNA demethylation machinery in 
zebrafish (17) suggests that like mammals, zebrafish might use methylation and 
demethylation to regulate epigenetic reprogramming. This further underscores 
the utility of this nonmammalian vertebrate in studying the impacts of DNA 
methylation in development and disease. These data suggest that zebrafish 
offers a unique opportunity to dissect possibilities of tissue-specific functions of 
various Dnmt3 isoforms in embryonic development.  
           To this end we have analyzed the expression patterns of zebrafish dnmt4, 
dnmt5, dnmt6, dnmt7 and dnmt8 at different stages of embryonic development. 
Further we have characterized antisense morpholinos for each of these genes to 
examine the gross morphological phenotypes and the impact of depletion of 
these enzymes on global methylation levels during embryognesis. 
          Such analyses will be useful in screening novel DNA methyltransferase 
inhibitors that are specific against different DNA methyltransferases. An 
important problem associated with the current DNA hypomethylating drugs is that 
they are not specific against any particular DNA methyltransferase thus causing 
unwarranted side effects. Zebrafish offers an economic and useful system to test 
the specificity of different DNA hypomethylating drugs against different isoforms 
of dnmts.  
          In this study we have characterized the embryonic expression patterns of 
dnmt4, dnmt5, dnmt6, dnmt7 and dnmt8 that are orthologs of either mammalian 
Dnmt3A or Dnmt3B in zebrafish. Based on previous data from our lab I 




methyltransferases in zebrafish and are required in a tissue-specific manner to 
guide organ development. 
 
2.2 Materials and methods 
2.21 Zebrafish maintenance 
          Zebrafish stocks were maintained in z-mods on a 14:10 hour light:dark 
cycle at 28°C in the Hunstman Cancer Institute  zebrafish fish facility using 
standard fish husbandry IACUC protocols. Fertilized embryos were grown at 
28.5°C. For whole mount in situ hybridization embryos were raised in 0.003% 
phenylthiourea to inhibit pigment formation.  
 
2.22 Zebrafish microinjections  
          Morpholino injections were done at 1-4 cell stage. Morpholinos were 
ordered from Gene Tools LLC. Morpholino oligonucleotides and the splice 
junctions they were designed against for dnmt4, 5, 6, 7, and 8 are shown in 
Table 2.1. 
 
2.23 Oligonucleotides and constructs 
          The GenBank accession numbers for dnmt4, 5, 6, 7, and 8 are 
NM_001025450, NM_001020479, NM_001018140, NM_001020476 and 
NM_001018134 respectively. Zebrafish dnmt4, 5, 6, 7 and 8 were cloned in 
pCRTOPOII vector. Splice check was performed using the primer sets shown in 





2.24 Whole mount in situ hybridizations 
          Zebrafish embryos at mentioned time points were fixed in sucrose buffered 
4% para-formaldehyde.  The embryos were washed in PBS, dehydrated and 
stored in methanol at -20°C.  Whole mount in situ hybridizations were carried out 
as described previously (18) using digoxigenin-labeled riboprobes for dnmt4, 
dnmt5, dnmt6, dnmt7, and dnmt8. 
 
2.25 Global DNA methylation assay by LC-MS 
          Embryos were collected at 24hpf and 72hpf and genomic DNA was 
isolated using Gentra Systems PURGENE DNA Purification kit. Global DNA 
methylation analysis was performed using liquid chromatography-mass 
spectrometry as described previously (20). 
 
2.26 Statistical analyses 
          Prism 4 (GraphPad Software, San Diego, CA) was used for statistical 




          To determined the dynamics of changes in the bulk DNA methylation 
levels in zebrafish development we used a mass spectrometry-based assay (20), 




levels of the 1hpf zebrafish embryo (mdC/dG content of 1.94% + 0.32% (ave + 
S.D.) in comparison to the 24hpf embryo (mdC/dG content of 6.89% + 0.36% 
(ave + S.D.). The global methylation levels of the whole adult fish is nearly the 
same as the 24hpf embryo: 6.74% + 0.51% (ave + S.D.). This difference in the 
genomic methylation levels of the 1hpf embryo and the 24hpf embryo suggest 
that during development of the newly fertilized embryo active DNA methylation 
must be occurring in the genome. However, it is not known if this methylation 
occurs in tissue-specific patterns. Also, which of the DNA methyltransferases are 
actively involved in conferring this de novo methylation are not known. It will be 
interesting to determine how early in embryonic development these bulk 
methylation patterns are re-established. Importantly, because the bulk 
methylation levels are representative of the silenced repetitive elements in the 
fish genome they cannot be used to elucidate the methylation dynamics at 
promoters of genes in different tissues.  
          A different approach needs to be employed to elucidate tissue-specific 
methylation patterns in embryonic development. The promoter methylation of 
genes in pure populations of different kinds of cell types from different organs 
needs to be used. Various techniques, such as bisulfite sequencing of target 
gene promoters, whole genome bislufite sequencing, and Methylated DNA 
immuno precipitation (MeDIP) and promoter array hybridization (aCGH) analyses 
can be performed. 
          To determine where dnmt4, 5, 6, 7, and 8 expressed in the zebrafish 




7, and 8 are expressed in a tissue-specific manner. The expression is observed 
both in common as well as discrete organs. At earlier stages e.g. 24hpf the 
expression of the dnmt4 transcript is ubiquitous in the anterior structures such as 
different parts of the brain, immature eyes, pharyngeal arches skeleton, and 
pectoral fin musculature. In the posterior structures dnmt4 expression is confined 
to the hematopoietic compartment, such as the artery and certain populations of 
blood cells (Figure 2.2).  
          By 72hpf the expression of dnmt4 becomes tissue-restricted and is 
robustly expressed in the tegmentum, telencepalon, diencephalon, ventricular 
zone, retina, pharynx, gut, pectoral fin, pharyngeal arches, artery and 
hematopoietic cells. These data are consistent with a previous report (21) that 
shows strong expression of murine Dnmt3b in the hematopoietic stem cells and 
uncommitted progenitor cells. Importantly, Dnmt4 exhibits 68% amino acid 
sequence identity with mouse DNMT3B (13). Despite the strong homology 
between dnmt4 and Dnmt3b, morpholino knockdown of zebrafish dnmt4 did not 
confer any phenotypic defects (5). 
          Dnmt5 is a ubiquitously expressed gene that is maternally supplied (Figure 
2.3). At 24hpf and 36hpf the dnmt5 gene is robustly expressed in a number of 
tissues including the brain, musculature, eyes, and the notochord suggesting it 
may be required for early stages of development. At around 72hpf the expression 
pattern of dnmt5 becomes very localized to the pharyngeal arches, jaws, 
intestine, pectoral fins, brain and the eyes. It is also expressed in a subpopulation 




          Dnmt6 transcripts in the embryos are also maternally supplied (Figure 2.4). 
The expression of dnmt6 at 24hpf is ubiquitous. However, by 48hpf the 
expression of dnmt6 becomes localized more in the anterior regions of the 
embryos particularly the brain, eyes and the fins, with some expression in the 
gut. Interestingly, dnmt6 appears to be expressed in the neural crest cells. This 
pattern of expression is consistent with the requirement of Dnmt3a in neuronal 
development (22). 
          Dnmt7 in zebrafish is also maternally supplied like the rest of the DNA 
methyltransferases. The expression of dnmt7 is very ubiquitous in early 
development. In late stages it is quite prominent in the brain, eyes, pharyngeal 
arches, pectoral fins and the gut. This is contrary to a previous report (23) that 
suggests that at 48hpf there is restricted expression of dnmt7. Interestingly, 
dnmt7 appears to be expressed in a subpopulation of blood cells at 48h. 
However, at 72hpf the expression does not seem to be as robust in the blood 
cells (Figure 2.5). It has been reported that dnmt7 methylates the ntl gene (5). 
However, the authors did not report if this methylation regulates promoter activity 
of ntl. Interestingly, these authors did not find any phenotypic defects in the 
dnmt7 morphants. 
          The expression pattern of dnmt8 at different time points is shown in Figure 
2.6. Dnmt8 is expressed ubiquitously at early time points particularly in the neural 
tissues and the pronephric ducts. It is expressed in the somites, brain, the 





          A previous report has suggested that knock down of dnmt4, dnmt5, dnmt6, 
dnmt7 and dnmt8 does not confer any gross morphological phenotypes in the 
morphants (5). Interestingly, the authors used translation-blocking morpholinos 
for their analyses, but did not verify the knock down of the protein levels because 
of lack of dnmt4, dnmt5, dnmt6, dnmt7 and dnmt8 antibodies.     
          Taking into consideration this lack of resource we employed a different 
approach by designing splice-blocking morpholinos for different splice junctions 
of the DNA methyltransferase genes. The antisense splice blocking morpholinos 
were designed for splice junctions in the N-terminus of the enzymes. A diagram 
of the zebrafish DNA methyltransferases showing the various domains in the N-
terminus is represented in Figure 2.7. The design of each morpholino and the 
junctions used is also represented in Figure 2.7.  
           Splice blocking morpholinos were injected into 1-4 cell stage embryos. 
Different morpholinos injections lead to different levels of survival in the 
morphants (Figure 2.9). The data from three separate experiments is plotted in 
this graph. Interestingly, dnmt4, dnmt5 and dnmt7 morphants showed decreased 
survival in comparison to the control injected embryos – 51%, 53% and 55% 
survival respectively in comparison to 79% 80%, and 93% survival of the control 
morphants. Verification of morpholino effect on splicing was performed at 24h. 
The reduction in spliced product for dnmt4, dnmt5, dnmt6, dnmt7, and dnmt8 and 
the formation of unspliced product is represented in Figure 2.8. 
          The five dnmt morphants showed different gross morphological defects. 




curvature defects were seen in dnmt5 and dnmt7 morphants. Prominent 
microphthalmia or small eyes were observed in dnmt4 and dnmt7. Interestingly, 
dnmt4 morphants displayed a lack of yolk sac extension and a globular yolk 
(Figure 2.10). Importantly, to determine the requirement of different dnmts in 
embryonic development it will be necessary to characterize what genes are 
affected in these morphants. 
          To determine if the dnmt4, dnmt5, dnmt6, dnmt7 and dnmt8 are indeed de 
novo DNA methyltransferases we performed LC-MS quantification of dC/dG 
content on the genomic DNA of these morphants at 24hpf and 72hpf. As, 
expected we did not observe appreciable changes in the levels of bulk 
methylation in the morphants and the controls Figure 2.11 
 
2.4 Discussion 
          Previous reports from our lab have demonstrated that zebrafish dnmt1 is 
expressed in proliferative tissues like retina, parts of the brain, pharyngeal arches 
and the gut (24). Morpholino-induced knockdown of dnmt1 leads to terminal 
differentiation defects of the pancreas, retina and the gut in 96hpf embryos.  
          However, the progenitor specification of these organs is unaltered, 
suggesting a role for dnmt1 in regulating terminal differentiation of the eyes, gut 
and pancreas (24). Importantly, knockdown of dnmt1 conferred 40% reduction in 
global genomic methylation levels (24) suggesting that like the mammalian 
derivative, zebrafish dnmt1 is a maintenance DNA methyltransferase. 




conserved catalytic domain has a 89% identity to the human protein (13). 
Complementation of the human derivative rescued the defects in dnmt1 
morphants, suggesting that DNMT1 might function in similar tissues. Recent 
findings from dnmt1 mutant lines in zebrafish (26) are in agreement with the 
molecular phenotypes observed in morpholino-induced knock-down studies (24). 
          Interestingly, zebrafish is the only organism in which transient knockdown 
of Dnmt2 reveals roles for this protein in embryonic development. Unlike the 
other family members of the zebrafish DNA methyltransferases Dnmt2 is an RNA 
methyltranferase (27). This is in agreement with the RNA methylating functions of 
mammalian DNA methyltransferases (28-31). This finding strongly supports the 
use of zebrafish as developmental model. The dnmt2 morphants harbor defects 
in terminal differentiation of the embryonic retina, liver and brain at 80hpf (27), 
indicating that zebrafish is a useful vertebrate model system to study tissue 
ontogeny.    
           dnmt3 morphants exhibit terminal differentiation defects in the brain while 
the specification and patterning of the brain was unaffected. This highlights the 
functions of this gene in tissue-specific terminal differentiation (19). Moreover, in 
this study we have also demonstrated that in zebrafish, dnmt1 and dnmt3 cannot 
complement for the loss of each other although both the proteins are expressed 
in the gut and the brain. This suggests that in spite of redundant expression 
dnmt1 and dnmt3 have tissue-specific functions. 
           The absence of a protein that resembles in sequence to Dnmt3l 




support in the fact that diploid androgenote and gynogenote zebrafish can 
survive to adulthood and are fertile, suggesting that monoallelic expression by 
imprinting likely does not occur in a developmentally regulated manner in 
zebrafish (34, 35).  
      However, another report indicates that there are parent-of-origin effects on 
methylation of transgene in zebrafish (36). Furthermore, transposable elements 
(sequences methylated by DNMT3L in mice) are known to be methylated in 
zebrafish (37). To date, the proteins that are involved in this phenomenon have 
not been identified in zebrafish. A thorough functional approach must be 
employed to identify functional similarities between zebrafish DNA 
methyltransferase proteins and the mammalian homologs to identify proteins and 
interacting partners that may be involved in imprinting or similar regulatory 
processes. 
          Although dnmt4, dnmt5, dnmt6, dnmt7, and dnmt8 have redundant 
expressions (as shown in Figures 2.2-2.6) they may have non-redundant 
functions depending upon various regulatory mechanisms that aid in activation or 
repression of the DNA methylatransferase (39, 40). In support of this idea we 
show that morpholino knockdown of different DNA methyltransferases confers 
different gross-morphological defects in the embryos (Figure 2.10). These 
differences may arise because the dnmts may affect different genetic targets. 
However, a detailed comparative analysis of the genetic targets needs to be 
performed to support this idea.  




zebrafish function as de novo DNA methylatransferases as seen by lack of 
changes in global DNA methylation levels in the morphants. This indicates that 
zebrafish dnmt4, dnmt5, dnmt6, dnmt7, and dnmt8 are functionally similar to 
mammalian Dnmt3a or Dnmt3b. However, functional assays need to be 
performed to determine the homology between the fish and the mammalian 
proteins. In this study we have characterized the expression patterns, and 
morpholinos for zebrafish dnmt4, dnmt5, dnmt6, dnmt7, and dnmt8. Because 
zebrafish dnmts are orthologous to mammalian DNA methyltransferases, 
























Figure 2.1. Dynamic changes in the bulk methylation levels of the zebrafish 
genome during development. LC-MS quantification was performed to analyze 
the bulk %5mdC/dG content at different stages of embryonic development. The 
newly formed zygote at 1hpf has a much lower bulk methylation than the 24hpf 
embryo. It is not known whether during the remethylation of the genome there is 
















Figure 2.2. Expression pattern of dnmt4 during embryonic development. 
Zebrafish dnmt4 is a maternally supplied transcript (black arrow) and is 
expressed in the eyes (red arrow), brain (green arrow), fins (brown arrow), 
pharyngeal endoderm (yellow arrow), gut (pink arrow) and a subpopulation of 










Figure 2.3. Expression pattern of dnmt5 during embryonic development. 
Zebrafish dnmt5 is a maternally supplied transcript (black arrow). dnmt5 is 
expressed in the eyes (red arrow) brain (white arrow), fins (yellow arrow), 
pharyngeal endoderm (pink arrow), gut (brown arrow) and  a subpopulation of 










Figure 2.4. Expression pattern of dnmt6 during embryonic development. 
Zebrafish dnmt6 is a maternally supplied transcript (pink arrow), and is 
expressed in the eyes (white arrow), brain (light blue arrow), fins (brown arrow), 









Figure 2.5. Expression pattern of dnmt7 during embryonic development. 
Zebrafish dnmt7 is a maternally supplied transcript (light blue arrow). dnmt7 has 
ubiquitous expression at 72h (pink arrow) suggesting that it may be required 
extensively during early embryonic development. It is expressed in the eyes 
(yellow arrow), neural tissue (brown arrow), musculature (green arrow), 
pharyngeal endoderm (red arrow), gut (white arrow) and a subpopulation of 









Figure 2.6. Expression pattern of dnmt8 during embryonic development. 
Zebrafish dnmt8  is a  maternally supplied transcript (pink arrow) and is robustly 
expressed in early development. The expression is prominent in the neural tissue 
at 24h (red arrow), robustly expressed in the pronephric duct (light blue arrow) at 
24h, 48 and 72h. It is expressed in the eyes (orange arrow), brain (yellow arrow), 














Figure 2.7. Morpholino design. The upper panel represents the domain 
structure of dnmts and the lower panel shows the design of the morpholinos. The 



























Figure 2.8. Knock down verification of dnmts in zebrafish embryos. 
Transcript levels of dnmt4, dnmt5, dnmt6, dnmt7, and dnmt8 were knocked down 
using antisense morpholinos. Total RNA was harvested from 24hpf controls and 
morphants. DNase1 treatment was performed before making cDNA. In each 
PCR reaction a loading control (28S) and water as negative control were used 
(data not shown). U-unspliced product, s-spliced product, co-control morphant, 














Figure 2.9. Percentage viability of dnmt morphants.1-4 cell stage embryos 
were injected with control or dnmt morpholino. The graph is representative of 
three sets of control or dnmt injections (n=3). The pooled total number of injected 
embryos for each category in the plot is N. N represents total # of embryos 
injected with dnmt morpholino, total # of embryos injected with same 
concentration of control morpholino. N for dnmt4=165,43; dnmt5=140/56; 
dnmt6=62,75; dnmt7=165,40, and dnmt8=97,53. The embryos that survive the 
dnmt morpholino injections displayed characteristic phenotypes of morphants 
and were embryonic lethal between 72h and 96h. The concentration for each 


















Figure 2.10. Dnmt morphants gross phenotypes. Gross morphological 
phenotypes on knockdown of dnmt4, dnmt5, dnmt6, dnmt7, and dnmt8 at 72h. 
Transcript levels of dnmt4, dnmt5, dnmt6, dnmt7, and dnmt8 were knocked down 
using antisense morpholinos. Interestingly, dnmt4, dnmt5, dnmt6, dnmt7, and 
dnmt8 displayed different gross morphological defects suggesting that these 
enzymes may have different contributions during embryonic development. 
















Figure 2.11. Bulk methylation levels in the genomes in dnmt morphants. 
LC-MS quantification was performed to analyze the bulk %5mdC/dG content of 
dnmt4, dnmt5, dnmt6, dnmt7, and dnmt8 at 24h and 72h. The Y-axis represent 
the % 5-mdC/dG, the open bars represent the WT and the solid bars represent 
the morphants. As expected these DNA methyltransferases do not regulate bulk 
methylation levels. However, it is not known if these enzymes have functions in 






Table 2.1. Morpholino and primer sequences. 




dnmt4 e9i8 AGCCACCTGAGGACACACAGGAAGC 
dnmt4 e7i8 AGGCATTGTATTTTAGTTACCTCTG 
dnmt5 e2i2 TGTCTTTTACCCCTTACCTAGCATC 
dnmt6 e5i4 TGGCTACCTGTAAGACAAGACAGTC 
dnmt7 e3i2 TGCACCTAAAAACAAGACAAAACAG 






Gene Forward Primer-1 Reverse Primer-1 
dnmt4-1   
dnmt4-2 
GATAATAAGGGCTTTGGTA
TTGG CTCAAGGGCCTGGAAGATC    
dnmt5 
ACACACTGACAACATCAAG
AG  tcagttcctcaacagcctat  
dnmt6  ATTCAGGTGGATCCAGGC CTGTTGCCTTTGAGTTCCTTC 





GACAG   
 Reverse Primer-2 Forward Primer-2 
dnmt4-1   
dnmt4-2 Cgtgattctgattggctgatg  
dnmt5 TGTCCAAATCCGACACCG  
dnmt 6   ATGGCTACAAATGTTAGTCTGG 
dnmt7  ATGGCTACAAATGTTAGTCTGG 
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          DNA methylation is an epigenetic mechanism important for transposon 
silencing, genome defense, imprinting, and gene regulation. During development, 
DNA methylation affects tissue specific terminal differentiation of various cell 
types across different vertebrate model systems (1-6). Based on substrate 
specificity DNMT1 is the primary maintenance DNA methyltransferase and 
DNMT3a and DNMT3b are the main de novo DNA methyltransferases (7), 
though some crossover likely occurs. Complete loss of Dnmt1 (8), Dnmt3a, or 
Dnmt3b `(9) (separately) are each incompatible with life, thus underscoring the 
critical role of these enzymes in regulating vital biological processes.  
          The hematopoietic system is a robust model system to study epigenetic 
decisions that regulate cell fate commitments (10-12), and aspects of DNA 
methylation have been addressed previously, primarily in mice. Functional 
knockout of Dnmt1 by removal of the catalytic domain of DNMT1 in the HSCs is 
incompatible with survival (13). On combining the hypomorphic Dnmt1 allele with 
the Dnmt1 null allele, these Dnmt1-/chip mice showed a severe reduction in the 
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Lymphoid Primed Multipotential Progenitors and a 2.7 fold enrichment of the 
long-term HSCs. Interestingly, the Dnmt1-/chip mice do not exhibit changes in the 
frequencies of differentiated myeloid and erythroid cells. In contrast, ablation of 
Dnmt1 in the hematopoietic compartment obtained by crossing Dnmt1fl/fl with 
interferon-inducible Mx-Cre transgenic mice do not exhibit hematopoietic defects 
in terminally differentiated blood and progenitor cell type (14). This observation 
suggests that although Dnmt1 may not be required for terminal differentiation of 
different lineages in hematopoiesis, roles for Dnmt3a and/or Dnmt3b remain.  
However, in transplantation assays (14)  Dnmt1 was shown to be required for 
self-renewal and differentiation of the HSC cells and for differentiation into 
mature myeloid cells. The studies discussed above do not reconcile, and indicate 
that Dnmt1 is either required solely for the generation of terminally differentiated 
cells of the lymphoid lineage (13) or the myeloid lineage (14). Also, this suggests 
that Dnmt3 family genes may play a role in regulating formation of terminally 
differentiated hematopoietic cells.  
Knock out of both the de novo DNA methyltransferases Dnmt3a and 
Dnmt3b in HSCs focused on the requirement of de novo methylation in HSC self-
renewal (15). However, knock out of both Dnmt3a and Dnmt3b in HSCs did not 
confer defects in the generation of lineage specific progenitors. This observation 
strongly suggests that de novo methylation is dispensable for lineage 
commitment process. However, neither this nor other studies (10, 13, 14) have 
investigated the contributions of Dnmt3a and Dnmt3b in terminal differentiation of 
mature blood lineages, which is the focus of our study. 
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In this report we show that zebrafish dnmt4 a homolog of the human 
DNMT3B regulates terminal differentiation of erythroid and myeloid lineages. 
dnmt4 morphants show a downregulation of erythroid and myeloid lineage cells. 
However, immature cells of both these lineages are expressed robustly 
suggesting that anemia and neutropenia occur due to defects in terminal 
differentiation rather than due to defects in the formation of lineage precursor 
cells. Notably dnmt4 morphants also display cranio-facial anomalies that together 
with the blood development abnormalities are reminiscent of the features 
observed in ICF (Immunodeficiency Cranio-Facial anomalies) syndrome arising 
due to mutations in DNMT3B. Because dnmt4 morphant embryos exhibit 
molecular defects that largely mimic defects in the ICF syndrome these 
morphants might be used as an in vivo system to dissect molecular pathways 
associated with this disease. We further show that retinoic acid signaling is 
perturbed in dnmt4 morphants and exogenous supplementation of ATRAL 
rescues the neutrophil lineage defects in dnmt4 morphants. Moreover, retinoic 
acid deficiency created by both genetic knockdown and pharmacologic inhibition 
of the pathway phenocopy the defects observed in dnmt4 morphants.  
 
3.2. Materials and methods 
3.2.1. Zebrafish maintenance 
          Zebrafish stocks were maintained in z-mods on a 14:10 hour light:dark 
cycle at 28°C using standard fish husbandry IACUC protocols. Transgenic 
Tg(fli1a:GFP) zebrafish were obtained from the N. Trede Laboratory. 
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3.2.2. Zebrafish microinjections  
          Morpholino oligonucleotides were ordered from Gene Tools LLC. The 
sequences for dnmt 4, 5, 6, 7, 8, p53, rdh1l and control morpholinos are provided 
in Chapter 2 and Table 3.1. The morpholino sequences for dnmt1 (4) and dnmt3 
(2) have been described elsewhere. Human DNMT3B, and DNMT3B catalytic 
mutant plasmids have been described elsewhere (2). Human DNMT3A plasmid 
was purchased from Origene. For RNA injections, 12pg of human DNMT3A, 
12pg of human DNMT3B and catalytically inactive human DNMT3B plasmids and 
15pg of capped and polyadenylated zebrafish dnmt4 mRNA were injected into 
one-cell stage wild type zebrafish embryos to test for rescue the defects in dnmt4 
morphants.  
 
3.2.3. Oligonucleotides and constructs 
          The GenBank accession numbers for dnmt4, 5, 6, 7, and 8 are 
NM_001025450, NM_001020479, NM_001018140, NM_001020476 and 
NM_001018134 respectively. Zebrafish dnmt4, 5, 6, 7 and 8 were cloned in 
pCRTOPOII vector. MJR provided clones for mpx, cmyb, spi1, gata1, and SAH 
provided clones for alphae1, alphae2, betae1, betae3. The oligo nucleotide 
sequences for cloning and confirming the splice check of the DNA 






3.2.4. Whole mount in situ hybridizations 
          Whole mount in situ hybridizations were carried out as described 
previously (16) using digoxigenin-labeled riboprobes for dnmt4, dnmt5, dnmt6, 
dnmt7, dnmt8, mpx, cmyb, spi1, gata1, alphae1, alphae2, betae1, betae3, 
ascl1a, and ifabp. 
 
3.2.5. Alcian Blue Staining 
          Alcian blue staining has been described in detail previously (2). The 
stained embryos imaged with Zeiss Axiovert100 microscope using an Olympus 
Magnafire color camera. 
 
3.2.6. Histological analysis 
          In situ stained embryos at mentioned time points were fixed, processed, 
and sectioned for histological analyses as described previously (2).  The sections 
were photographed with Zeiss Axiovert100 microscope using an Olympus 
Magnafire color camera. 
 
3.2.7. Whole mount double fluorescent in situ hybridizations 
          Digoxigenin (DIG)- and fluorescein (FITC)-labeled UTPs were used to in 
vitro transcribe dnmt4 and cmyb antisense probes according to the 
manufacturer’s instructions (Roche, Palo Alto, CA). Embryos were fixed and 
processed as described for WISH. Cy3:Tryamide and FITC:Tryamide were 
synthesized following protocols mentioned on the website Xenbase. Dnmt4-Dig 
  
83 
probe was incubated with primary antibody (anti-DIG-POD Fab Fragments 
1:1000 dilution in block) and developed in PBST, 0.01 M Imidazole and 1:500 
tyramide–Cy3.  Cmyb-Fluo probes were detected with anti-Flu-POD Fab 
Fragments 1:1000 and developed in PBSTI, 0.001% H2O2 and 1:1000 tyramide-
FITC at room temp for 60 min. The embryos were photographed using Olympus 
FV1000XY microscope and imaged with Fluoview software.  
 
3.2.8. Histochemical staining 
          Hb activity was detected in whole embryos by histochemical staining for 
Hb using o-dianisidine as described previously (17). Sudan Black histochemical 
staining for detecting lipophilic mature neutrophils was performed as described 
previously (18) . The embryos were stored in 80% glycerol and photographed 
with Zeiss Axiovert100 microscope using an Olympus Magnafire color camera. 
 
3.2.9. Morphometry 
          To analyze the morphology of the circulating peripheral blood cells tails of 
72h embryos morphometric analyses was performed as described (19). The cells 
were imaged at high power using Zeiss Axiovert100 microscope using an 








3.2.10. Genomic DNA isolation and global DNA methylation  
assay by liquid chromatography-mass spectrometry 
          Embryos were collected at 24 and 72 hpf, and genomic DNA was isolated 
using Gentra Systems PURGENE DNA Purification kit. Global DNA methylation 
analysis was performed using liquid chromatography-mass spectrometry as 
described previously (20). 
 
3.2.11. PCR, gene expression and methylation analysis 
          Total RNA was harvested and treated with DNase1 to remove gDNA 
contamination. For whole genome expression analyses 24h and 72h RNA from 
WT and dnmt4 mo1 were labeled with Cy3 and Cy5 dyes and hybridized on 
Agilent 2-color Zebrafish v3 Gene Expression (4x44K) microarray in triplicates. 
cDNA for PCR reactions was synthesized from 2 µg of total RNA using 
Superscript III (Invitrogen). PCR was performed using the Roche Lightcycler 
instrument and software, version 3.5 (Roche Diagnostics). A template-free 
negative control was included in each experiment.  The sequences of PCR 
primers used have been provided in Table 3.1.  
 
3.2.12. MeDIP (Methylated DNA Immuno Precipitation)  
and array hybridization 
          The procedure used for MeDIP has been described previously (21). The 
immuno precipitated DNA was amplified using whole genome amplification kit 
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(Sigma Aldrich). The amplified DNA was labeled with Cy5 and Cy3 and was 
competitively hybridized to custom-designed 244K oligonucleotide zebrafish 
promoter arrays (Agilent Inc). 
 
3.2.13. Statistical analyses for whole genome 
expression and MeDIP analyses 
          The probes on the tiling arrays were mapped to the most recent zebrafish 
genome (Zv9). Statistical analysis of the MeDIP-chip datasets was performed 
using the SLAM software (http://jlab.byu.edu/SLAM/), which is adapted from 
normalization method described previously (22). The gene expression data were 
also normalized using a variation Song et al (22). GoMiner (23) was used to 
identify under and over represented Gene Ontology terms.  
 
3.2.14. Statistical analyses 
          Prism 4 (GraphPad Software, San Diego, CA) was used for statistical 
analyses. Results of statistical analyses are provided in Table 3.2. Values were 
calculated using Student’s t test. The quantitative data is representative of at 
least three independent experiments. 
 
3.2.15. Drug treatments 
          To rescue the retinoic acid deficiency in dnmt4 and control morphant 
embryos were treated with 0.3µM all-trans-retinaldehyde (RAL; Sigma-Aldrich) at 
10h, 24h, 48h and 72h for 30 min. After each treatment the embryos were 
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washed three times with embryo water. For creating retinoic acid deficient 
embryos DMSO or 5µM 4-diethylamino benzaldehyde (DEAB; Sigma-Aldrich) a 
competitive inhibitor of aldehyde dehydrogenases was added to plates containing 
wild type embryos at 5h. The embryos were allowed to grow till 72h.  
 
3.3. Results 
3.3.1. dnmt4 is expressed in the hematopoietic  
cells in zebrafish larvae 
          To clarify the roles of DNA methylation during various steps of 
hematopoiesis we asked which of the DNA methyltransferases are expressed in 
the hematopoietic compartment of the zebrafish embryos. Unlike mammals, 
zebrafish have eight DNA methyltransferase genes. Based on sequence 
homology and functional complementation experiments dnmt1 closely resembles 
human DNMT1 (4). Zebrafish dnmt2, like human DNMT2, behaves functionally 
as an RNA methyltransferase (24), and therefore was not addressed further. 
There are six DNMT3-family genes in zebrafish in comparison to the three 
mammalian genes (25). Based on the sequence alignments dnmt3, dnmt4, 
dnmt5 and dnmt7 resemble DNMT3B, where as dnmt6 and dnmt8 demonstrate 
higher sequence similarity to DNMT3A. However, complementation and/or 
biochemical analyses with human proteins are required to determine the 
functional homology of the zebrafish proteins to their human counterparts. To 
determine which of the dnmts are expressed in the hematopoietic compartment 
of the zebrafish embryos we performed in situ hybridization analyses of the 
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zebrafish dnmt1, dnmt3, dnmt4, dnmt5, dnmt6, dnmt7 and dnmt8. We also cross 
sectioned the embryos at 72h to determine the anatomical location of the 
different transcripts. Interestingly, we find that dnmt4 is a maternally-supplied 
transcript is robustly expressed in the hematopoietic compartment of zebrafish 
embryos at 24h, 48h, 72h, and 96h (Figure 3.1). However, it is not limited to the 
blood lineage. The expression of the dnmt4 transcript is ubiquitous in the anterior 
structures, including parts of the brain, eyes, pharyngeal arches skeleton, and 
pectoral fin musculature. By 72h the expression of dnmt4 becomes very specific 
and is robustly expressed only in the tegmentum, telencepalon, diencephalon, 
ventricular zone, retina, parynx, gut, pectoral fin, pharyngeal arches, artery and 
hematopoietic cells (Figure 3.1). Notably, in the posterior structures dnmt4 
expression is limited to the hematopoietic compartment such as the artery and a 
subset of the blood cells. dnmt4 sense strand probe was used as a control 
(Figure 3.1) and showed no signal.  
          We next analyzed the anatomical locations of the antisense dnmt4 probe 
by cross-sectioning digoxigenin labeled antisense dnmt4 probe stained embryos 
at 24h, 48h, and 72h. (Figure 3.2) shows the expression of dnmt4 in the dorsal 
aorta of the 72h embryo. Cross-sections of 24h and 48h dnmt4 stained embryos 
also show robust expression of dnmt4 in the dorsal aorta (data not shown). To 
further test for dnmt4 expression in the hematopoietic cells of the zebrafish 
embryos we performed double fluorescent in situ hybridization analysis of 
fluorescein labeled cmyb antisense probe and cy3 labeled dnmt4 antisense 
probe (Figure 3.2 lower panel). dnmt4 transcripts co-localize with the transcripts 
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of cmyb in the hematopoietic cells present in the caudal hematopoietic tissue 
(CHT) of the embryos at 72h. This data is consistent with a previous report (10) 
that shows strong expression of murine Dnmt3b in the hematopoietic stem cells 
and uncommitted progenitor cells.   
          We next addressed the expression of all other DNMTs in the 
hematopoietic cells at 72h (Figure 3.3). In spite of a significant overlap in the 
expression patterns of these genes in various organ systems the other DNA 
methyltransferases dnmt1, 3, 5, 6, 7, and 8 are not expressed in the 
hematopoietic compartment (by in situ hybridization analyses), the CHT region of 
the zebrafish embryos at 72h. We cross sectioned in situ stained embryos to 
investigate the anatomical localization of these transcripts. Although dnmt4 is 
expressed in other tissues, those tissues also harbor other DNMT3 paralogs.  In 
contrast, the apparent specificity of dnmt4 for expression in the blood lineage at 
72h prompted our examination of roles for dnmt4 in blood development, as the 
potential for redundancy with other DNMTs is minimized.  
 
3.3.2. Transient knockdown of dnmt4  
with antisense morpholino  
          We tested a role for dnmt4 in zebrafish hematopoiesis by a loss-of-function 
approach using antisense morpholinos. The domain structure of dnmt4 has a 
characteristic regulatory N terminal with the PWWP and PHD-like domains and 
an evolutionary conserved C terminal catalytic domain (Figure 3.4). Due to the 
lack of availability of antibodies against the zebrafish Dnmt proteins we have 
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used morpholinos designed to interfere with RNA splicing instead of those 
blocking translation. We designed two nonoverlapping antisense morpholinos, 
one against the exon 8 and intron 9 splice junction of dnmt4 (mo1, as shown in 
Chapter2) and a second against the exon 7 and intron 8 junction (mo2, data not 
shown). We also used a control morpholino bearing a five base pair mismatch 
from the first morpholino design.  
          We find that dnmt4 mo1, but not the control morpholino, blocked the 
formation of the spliced product with an efficiency of nearly 90% (Chapter 2, 
Figures 2.7 and 2.8). On sequencing the unspliced product we found that the 
retention of the intron 9 induced a stop codon in the protein before the PHD-like 
domain (indicated by an asterisks in Figure 3.4). This suggests that the dnmt4 
transcript containing the unspliced intron will not lead to the formation of a 
functional protein.  
          We have previously demonstrated that dnmt1 is a maintenance DNA 
methyltransferase in zebrafish as antisense morpholino knockdown of dnmt1 but 
not dnmt3 lead to a reduction in global methylation levels (2,4). Consistent with 
reports that Dnmt3b family enzymes are de novo DNA methyltransferases and 
their knockout does not lead to decrease in global DNA methylation levels (9), we 
observed no significant changes in the levels of global DNA methylation (as 
measured by LC-MS) in dnmt4 morphants in comparison to the wild type 
embryos at 24h and 72h (Chapter 2, Figure 2.11) . Also, in agreement with this 
idea that zebrafish dnmt4, 5, 6, 7,and 8 are homologs of human DNMT3A or 
DNMT3b and that they are not required in maintenance of bulk methylation 
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levels, antisense splice blocker morpholino knockdowns of dnmt5, 6, 7, and 8 
also do not lead to a loss in genome-wide methylation of the zebrafish embryos 
as measured by LC- MS quantification (Chapter 2, Figure 2.11). To test whether 
the defects in the dnmt4 morphant embryos were specific, we tested dnmt4 mo2, 
which conferred similar phenotypic and molecular defects (data not shown). This 
stark similarity produced by the two morpholinos and the rescues by dnmt4 RNA 
(Figure 3.8.) help establish the specificity of the dnmt4 knockdown.  
 
3.3.3. dnmt4 morphants have specific defects  
          Transient knock down of dnmt4 by both the morpholinos mo1 and mo2 
cause lethality between 3 and 4dpf, underscoring the necessity of this enzyme 
for viability. Around 24hpf the yolk sac extension started to become thinner and 
by 48hpf the embryos lost their yolk sac extension. The prominent distinguishing 
phenotypes of the dnmt4 morphants at 72hpf were lack of pectoral fins, 
hydrocephalus of the hindbrain, defects in formation of jaws, smaller eyes and 
head. The body of the morphant was thinner with tail curvature and displayed a 
lack of yolk sac extension. Also, these morphants showed pericardial edema and 
hypochromic blood cells circulating in the vasculature. These defects were not 
observed in the dnmt4 control morpholino injected embryos (Figure 3.4). To 
determine if the dnmt4 morphants were developmentally delayed and were 
defective in the formation of multiple organ systems we analyzed them for the 
formation of the gut and the brain. We chose these organs because dnmt4 is 
robustly expressed in these structures. Also, we have earlier established that 
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dnmt1 and dnmt3 in zebrafish are required for the terminal differentiation of 
intestinal cells and brain, respectively (2,4). In support of the idea of tissue-
specific functions of the DNA methyltransferases we show that dnmt4 morphants 
do not exhibit a terminal differentiation defects in the intestines and brain as seen 
by the expression of ifabp and zash1a respectively (data not shown). Apart from 
the expression of dnmt4 in the hematopoietic compartment dnmt4 is also robustly 
expressed in the immature eyes as seen in the cross section of 24hpf embryos 
stained with dnmt4 (data not shown). Importantly, knockdown of dnmt4 causes 
disruption of the entire eye morphogenesis. The dnmt4 morphant eyes are 
mirophthalmic, have abnormal lens structure and exhibit a complete lack of 
retinal lamination. At the molecular level dnmt4 morphants harbor proliferating 
retinal progenitors (crx), amacrine cells, immature cone and rod cells (neurod), 
but show reduced differentiated cells of retinal ganglion cell layer and retinal 
nuclear cell layer (isl1). Moreover dnmt4, morphants lack expression of irbp 
(interphoto receptor retinoid binding protein), a marker for terminally 
differentiated retinal cells. Interestingly the overall developmental defects in the 
gross morphology of the dnmt4 morphants recapitulate the defects seen in the 
murine Dnmt3b knockout model and are also reminiscent of some of the defects 
observed in ICF syndrome arising from missense mutations in DNMT3B (26).  
Although we find other affected tissues, this study focuses on the impact of 






3.3.4. Erythrocyte maturation is affected  
in dnmt4 morphants 
          Because dnmt4 was found to be expressed in the hematopoietic 
compartment of zebrafish embryos we wanted to know if the dnmt4 morphants 
were compromised in the formation of blood cells. Indeed the dnmt4 morphants 
were severely anemic and showed a lack of hemoglobinization as measured by 
reduction in o-dianisidine positive cells at 48hpf and 72hpf (Figure 3.5). However, 
there was no apparent defect in specification of the red blood cells as observed 
by the expression of gata1, alphae1, alphae2 and betae1 globin expression 
(Figure 3.6). To determine the morphology of erythrocytes in dnmt4 morphants 
we performed them by Wright-Giemsa staining. Erythrocytes in 72hpf dnmt4 
morphant embryos appeared immature in comparison to the control morphants 
(Figure 3.5). The morphant blood cells appeared to have a decondensed nuclei 
with an increased nuclear to cytoplasmic ratio. Notably the cytoplasm of the 
dnmt4 morphant erythrocytes showed a purplish staining of the cytoplasm 
instead of the reddish hue observed in hemoglobinized control cells. To 
determine whether this lack of hemoglobinization of the peripheral blood cells in 
the morphant embryos was due to the morpholino-induced increased levels of 
p53 (27) we co injected the dnmt4 morpholino with a p53 morpholino and 
observed that this did not rescue the robust downgulation of o-dianisidine stained 
cells (data not shown). This lack of rescue suggested that defects in erythroid 
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maturation in the dnmt4 morphants was not due to off-targets effects of the 
morpholino. 
 
3.3.5. dnmt4 morphants are neutropenic  
          To determine if dnmt4 morphants harbored defects in other hematopoietic 
lineages we interrogated expression of myeloid lineage markers. Interestingly 
dnmt4 morphant embryos showed robust down-regulation of terminal neutrophil 
differentiation as tested by staining with the lipophilic dye Sudan Black (Figure 
3.7). Similar to the erythroid lineage, progenitors of the neutrophil lineage and 
immature neutrophils persisted in morphants as evidenced by the expression of 
spi1 (data not shown) and mpo respectively (Figure 3.7). Interestingly the mpo 
positive cells were also found to be mislocalized outside the CHT region. This 
could be a result of genes and pathways required for homing of the neutrophils. 
This observation further corroborates the previous reports that myeloid-specific 
genes Mpo, Cxxcr and Gadd45a have differential levels of methylation in 
uncommitted and committed progenitor cells (10). We were unable to investigate 
the effects of dnmt4 knockdown on T and B cell development because of 
morphant lethality (around 3.5 days) prior to lymphoid population of the thymus 
(28).  
 
3.3.6. dnmt4 morphants do not have vasculature defects 
          Since hematopoietic stem cells and the endothelial cells in the aorta gonad 
mesonephros region are believed to arise from common precursor cells of 
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hemogenic endothelium (29) we asked if similarly to blood cells, formation of the 
vasculature was also defective in the dnmt4 morphants. To this effect we injected 
dnmt4 and the control morpholinos into the Tg(fli1a:GFP) zebrafish. Confocal 
imaging of transgenic morphant embryos revealed that dnmt4 morphants had 
intact vasculature (data not shown). This again suggested that rather than 
pervasive developmental defects, dnmt4 morphants harbored tissue-specific 
defects. dnmt4 morphants showed defects in terminal differentiation of the 
hematopoietic cells but the vasculature formation was unaffected. We attributed 
the distortion of the inter-somitic vessels from V- to U shape, to the malformation 
of the somites rather than to defects in vasculature formation itself. This 
observation is in agreement with a previous report that treatment of zebrafish 
embryos with the demethylating agents 5-azacytidine and 5-aza-2deoxycytidine 
leads to abnormal somite patterning (30). However, the exact contribution of 
DNA methyltransferases in somite formation and patterning requires further 
investigation. 
 
3.3.7. Human DNMT3B complements dnmt4 
 loss in zebrafish 
          To address the functional relevance of our findings, we sought to 
determine in DNMT3B, the human homolog of dnmt4 could rescue dnmt4 
morphants. Toward this goal, we co-injected GFP-tagged clones of catalytically 
active and inactive versions of human DNMT3B with dnmt4 morpholino (Figure 
3.8). Indeed, as hypothesized, catalytically active human DNMTB but not the 
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inactive derivative rescues dnmt4 morphants. This suggests that zebrafish dnmt4 
and human DNMT3B are functionally homologous and that catalytic activity of 
the DNMT protein is required for its function in hematopoietic cells. The co-
injection of human DNMT3B partially rescued the defects of the erythroid lineage 
as seen by increase in the o-dianisidine positive cells (Figure 3.9) and myeloid 
lineage evidenced by the rescue of mislocalized of mpo-positive cells (Figure 
3.9). In addition to the partial rescue of hematopoietic differentiation, catalytically 
active DNMT3B also markedly improved gross morphological defects in dnmt4 
morphants (Figure 3.8). Recent reports (31,32) have shown that mutations in 
DNMT3A are involved in MDS and AML. To determine if dnmt4 was functionally 
similar to human DNMT3A we tried to rescue dnmt4 morphants with human 
DNMT3A. Co-injection of GFP-tagged plasmid containing full length human 
DNMT3A did not rescue the defects of dnmt4 morphants (data not shown). To 
verify that co-injected DNMT3A was expressed in vivo in dnmt4 we over-
expressed GFP-tagged DNMT3A constructs by transient transfection in SW480 
cells. As expected we observed expression of GFP in the nucleus of the cells 
suggesting that these fusion proteins were indeed being expressed and were 
localizing to the nucleus correctly (Figure 3.8). 
 
3.3.8. Hematopoietic defects are not recapitulated  
in other dnmt morphants  
          We hypothesized that dnmt4 regulates zebrafish hematopoiesis in a 
tissue-specific manner. To show that this defect was specific to dnmt4 we 
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knocked down the levels of the other DNA methyltransferases dnmt1, 3, 5, 6, 7 
and 8. The design of the morpholinos and the verification of the knockdown of 
transcripts of dnmt5, 6, 7 and 8 are shown in Chapter 2, Figures 2.7 and 2.8). 
The comparison of the 72hpf morphant phenotypes of the dnmt4, 5, 6, 7 and 8 
show different morphological phenotypes resulting form transient knock down of 
these genes. However, dnmt5, 6, 7 and 8 morphants do not show mis-expression 
of o-dianisdine (Figure 3.12) mpo-positive cells (Figure 3.13). Also, dnmt1 and 
dnmt3 morphants at 72hpf do not exhibit hematopoietic defects as shown by the 
o-dianisidine staining (data not shown) and normal expression of the mpo-
positive cells (data not shown). 
 
3.3.9. Dnmt4 morphants are retinoic acid deficient 
          We wanted to investigate the pathways that were disrupted in the dnmt4 
morphants. We decided to take a candidate approach and investigated different 
pathways that could be downstream targets of dnmt4. In this approach we took 
hints from our 72h whole genome expression array data and overall defects 
observed in the dnmt4 morphants. One of the candidate pathways that we 
investigated was retinoic acid (RA), signaling pathway. This pathway is 
conserved across species and is required for proper embryonic development of 
multiple tissues (33). Both excess and deficiency of this morphogen causes 
teratogenicity in embryos. Retinoic acid deficiency in zebrafish embryos causes 
pleiotropic effects some of which include loss of pectoral fins, heart enlargement, 
loss of jaw formation, defects in retina, brain, somite, and intestinal development 
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(34). Apart from these tissues RA is required for the formation of hematopoietic 
cells (35). Importantly, RA is successfully used in clinic as differentiation inducing 
therapy for the treatment of acute promyelocytic leukemia (APL).  
 
3.3.10. Treatment of dnmt4 morphants with  
retinoic acid rescues dnmt4 morphants 
          As our results suggested retinoic acid deficiency in dnmt4 morphants, we 
asked if treatment with all-trans retinaldehyde would rescue the mislocalization of 
myeloid cells in dnmt4 morphants. All-trans retinaldehyde treatment rescued the 
mislocalization of the mpo positive cells in the dnmt4 morphant embryos, 
corroborating our hypothesis that the RA pathway is one of the major 
downstream targets of dnmt4 (Figure 3.10).  
 
3.3.11. Retinoic acid deficiency phenocopies  
dnmt4 morphants 
          To evaluate if retinoic acid deficiency in WT fish would lead to similar 
defects in mpo-positive cells and terminal differentiation of the neutrophils we 
treated wild type embryos with DEAB, a nonspecific inhibitor of retinaldehyde 
dehydrogenases in zebrafish (Figure 3.11). In accordance with our hypothesis 
that retinoic acid deficiency causes lack of terminal differentiation of the myeloid 
population in zebrafish embryos we observed that the DEAB-treated embryos 
phenocopied both the myeloid and erythroid misregulation of the dnmt4 
morphants (Figure 3.11). To determine if genetic knockdown of RA biosynthetic 
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pathway would yield similar results we knocked down rdh1l in embryos. The 
rdh1l morphants phenocopied both dnmt4 morphants and DEAB treated embryos 
(Figure 3.11), supporting a causative role for retinoic acid deficiency in the 
hematopoietic defects in of dnmt4 morphants.  
 
3.4. Discussion 
          In the present study we have identified that zebrafish dnmt4, a homolog of 
human DNMT3B regulates terminal differentiation of erythroid and myeloid cells. 
Terminal differentiation of blood lineages is an important process for converting 
immature committed cells to mature functional cells. Defects in this process are 
often observed in hematological disorders like Myelodysplastic Syndromes 
(MDS) (36). MDS are disorders of the HSCs that are characterized by ineffective 
hematopoiesis leading to peripheral blood cytopenias. Also, hematopoietic 
diseases harbor aberrant expressions of DNMTs (37,38), and mutations of de 
novo DNA methyltransferases (32,39). A striking hallmark of hematopoietic 
diseases is de novo promoter hypermethylation (38,40-46) and subsequent 
transcriptional silencing of tumor suppressor genes. This phenomenon may be 
associated with either transcriptional deregulation of DNA methyltransferases 
themselves or the interacting partners of the DNMTs that may recruit them 
aberrantly to promoters of regulatory proteins.  Thus to better understand 
deregulations associated with hematopoietic transcriptional programs exact 
contributions of different DNA methyltransferases warrants further investigations.  
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The principal findings of this report are that (1) dnmt4 is expressed in the 
hematopoietic compartment of the zebrafish. (2) Only dnmt4 and not the other 
dnmts are required for the formation of the terminally differentiated cells of the 
myeloid and erythroid lineages. (3) The defects in dnmt4 morphants are rescued 
with complementation of the functionally active version of the human DNMT3B. 
(4) The defects in the maturation of the myeloid cells of the dnmt4 morphants are 
rescued by treatment of ATRAL. (5) Both pharmacologic and genetic knockdown 
of the retinoic acid biosynthetic pathway phenocopies the hematopoietic defects 
in dnmt4 morphants. Our study provides a model where retinoic acid mediates 
the effect of the de novo methyltransferase dnmt4 during normal blood 
development in zebrafish.  
          To model the ICF syndrome mice carrying two missense that lead to partial 
loss of function of Dnmt3b were generated (26). These mice phenocopy some 
aspects of the human ICF disease. They displayed facial dysmorphism and low 
weight at birth. However, unlike agammaglobinemia that is observed in most 
patients these mice display defects in T cell lineage. After birth, the number of 
thymocytes in ICF mice were reduced due to apoptosis in the thymus suggested 
that Dnmt3b activity is essential for the survival of T cells in the thymus. 
However, unlike ICF patients these mice did not display changes in mature B cell 
populations. Interestingly, decreased levels of T cells are not as frequently 
observed in ICF patients Instead, the patients largely suffer from 
agammaglobinemia. However, atleast one patient has been described with 
suffering from anemia and neutropenia (47). These findings suggest that the ICF 
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patients suffer from multiple complications and the clinical manifestations may be 
diverse. 
          At the cytogenetic level the ICF mice display hypomethylation of 
centromeric minor satellite DNA and juxtacentromeric major satellite DNA. 
Perhaps, such differences in cytogenetic pathophysiology may arise because of 
the differences in the genomes of mice and humans. Thus mice show more 
extensive DNA hypomethylation and the kind of immunological dysfunction is 
different. Importantly, because of the rare numbers of available ICF patient 
samples (nearly 50 reported cases), it is be important to develop new model 
systems that will recapitulate different aspects of the disease. Because most 
disease models only phenocopy certain aspects of the disease cumulative data 
from multiple model systems may be useful in generating a better understanding 
of the disease. Here we present data describing a zebrafish model of 
hypomorphic DNMT3B that partially phenocopy the ICF patients in harboring 
cranio facial defects of ICF patients. In addition they exhibit profound neutropenia 
and anemia. The dnmt4 morphants will be useful in dissecting the functions of 
DNA methylation in cranio facial development and developmental roles of 
DNMT3B that may be critical for the development of ICF syndrome. 
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Figure 3.1. dnmt4 is expressed in the hematopoietic cells in zebrafish. 
Whole mount in situ staining for dnmt4 in zebrafish at 72h using antisense 
strands and 72h sense strand. Comparison of expression pattern of dnmt4 at 
48h, 72h and 120h showing the expression of dnmt4 in the hematopoietic 








Figure 3.2. dnmt4 is expressed in the hematopoietic cells. Cross section of 
dnmt4 stained fish at 72hpf a-neural tube, b-myotomes, c-horizontal septum, d-
notochord, e-hypochord, f-dorsal aorta, g & h –pronephric ducts, i-posterior 
cardinal vein, j-gut. Lower panel shows dnmt4 expression co localizes with 








Figure 3.3. Other dnmts are not expressed in the hematopoietic cells in 
zebrafish embryos at 72h. To determine whether there is redundancy in the 
expression of dnmts in the hematopoietic compartment at 72h we analyzed the 
expression of dnmt4, dnmt5, dnmt6, dnmt7 and dnmt8 by in situ hybridization. 
The other dnmts were not expressed in the CHT region. We also cross sectioned 
these embryos at 72h to analyze the expression of the transcripts in the dorsal 










Figure 3.4. Knock down of dnmt4. (A) The domain structure of dnmt4. The 
asterisk denotes the inclusion of a stop codon in the protein on translation of the 
unspliced product. (B) The gross morphological defects observed in the dnmt4 














Figure 3.5. Transient knock down of dnmt4 affects onset of erythroid 
differentiation in zebrafish embryos at 48h and 72h.Correct maturation or 
hemoglobinization of the embryonic erythroid cells does not occur in dnmt4 
morphants: The onset of erythrocyte differentiation is analyzed by o-dianisidine 
staining. Dnmt4 morphants at 48h and 72h show anemia and decreased somitic 
iron stores. (Lower panel) Peripheral blood smear of zebrafish embryos at 72 
hours shows more immature cells as seen by increased nucleus to cytoplasm 
ratio in comparison to the control morpholino. Also, the cytoplasm of the dnmt4 
morphants show lesser hemoglobinization of the cytoplasm (bluish color of the 
cytoplasm) in comparison to the reddish color of the cytoplasm in the control 
morphants. Note the difference in the decondensed nuclei of the dnmt4 
































Figure 3.6. Specification of erythroid lineage is unaltered in dnmt4 
morphants. Transient knock down of dnmt4 affects onset of erythroid 
differentiation in zebrafish embryos at 48h and 72h but not specification of the 
erythroid lineage and formation of progenitors. RBC specification (gata1) and 





















Figure 3.7. Transient knock down of dnmt4 causes reduction of mature 
lipophilic neutrophils Sudan Black histochemical staining was used for 
detecting lipophilic mature neutrophils in dnmt4 morphants. The sudan black 
positive cells are down regulated in the dnmt morphants embryos in comparison 
to the 80h control embryos (upper panel and lower graph). W- wild type embryo 
and D4 –dnmt4 morphant embryo. However, the immature neutrophils were 
expressed in the dnmt4 morphants as assessed by the expression of mpo 


























Figure 3.8. Rescue of the gross morphological phenotypes of the dnmt4 
morphants at 72h. The vectors encoding the human proteins used to rescue the 
dnmt4 mo1 defects are expressed correctly and localize to the nucleus of the 
cells in culture (Upper Panel) Overexpression of vectors used for rescue 
experiment. SW480 cells were (a) untransfected or tranfected with (b) pCMV6-
AC-GFP clone containing DNMT3A transcript variant1 (c) pcDNA-DEST53 vector 
containing DNMT3B and (d) pcDNA-DEST53 vector containing DNMT3B 
catalytic mutant. The cells were transfected with the respective clones after 24h 
of plating. After 48h of transfection IHC was performed on the cells and washed 
and imaged with 60X oil immersion lens using a Nikon A1R/A1 confocal 
microscope. DAPI – Blue. Over-expressed exogenous DNMT3A, DNMT3B and 
DNMT3B catalytic mutants in Green. (Lower Panel) Dnmt4 is a functional 
homolog of the human DNMT3B. Dnmt4 morphants (2) show smaller heads, 
mircophthalmic eyes and yolk tube malformations that are rescued by co-
injection of catalytically active dnmt4 (4), human DNMT3B (5) and not by 
catalytically inactive zebrafish dnmt4 (3) catalytically inactive human DNMT3B (6) 




































Figure 3.9. Rescue of the mpo misexpression and o-dianisidine staining in 
the dnmt4 morphants with injection of dnmt4 RNA and DNMTB. Upper panel 
shows mpo expression and lower panel shows o-dianisidine staining. A1, B1 
control morphants, A4, B4- dnmt4 morphants, A2, B2-dnmt4 morphants + dnmt4 
RNA, A5, B5- dnmt4 morphants + mutant dnmt4, A3, B3-dnmt4 morphants + 










Figure 3.10. Treatment of dnmt4 morphants with retinaldehyde rescues the 
misloclization of mpo positive cells. Treatment of control morphants with RAL 
does not alter the distribution of mpo. (95%, n=45), data not shown. Treatment of 
DEAB alters mpo distribution like dnmt4 morphants (5%, n=55). Mislocalization of 
mpo cells in DEAB treated fish is rescued by treatment with RAL (45%, n=120). 
The dnmt4 morphants (Dnmt4 mo1) shows altered mpo mislocalization (10%, 
n=50), which is rescued by treatment with RAL shown in middle panel (rescue 
50%, n=80). The % represents the embryos showing WT stain. The total number 







Figure 3.11. Retinoic acid deficiency phenocopies erythroid 
hemoglobinization and mpo defects seen in dnmt4 morphants. Retinoic acid 
deficient fish created by pharmacologically blocking retinoic acid synthesis with 
DEAB an inhibitor of raldhs in zebrafish leads to erythroid hemoglobinization 
defects (95%, n=55). However, the expression of alphae1, alphae2, are 
significantly unaltered (100% embryos show WT stain, n=25 each). The DEAB 
treated embryos display similar mislocalization of the mpo positive cells (95%, 
n=50). Retinoic acid deficiency created by knocking down the levels of rdh1l 









Figure 3.12. The expression of o-dianisidine positive cells in other dnmt 
morphants at 72h. On investigating the expression of o-dianisidine positive cells 
in dnmt5 (70%, n=30), dnmt6 (100%, n=30), dnmt7 (72%, n=35) and dnmt8 
(100%, n=25) morphants we saw that the expression of o-dianisidine positive 
cells was significantly unaltered in comparison to the control morphants. The 
expression of o-dianisidine positive cells in dnmt4 morphants at this stage was 












Figure 3.13. The expression of mpo in other dnmt morphants at 72h. On 
investigating the expression of myeloperoxidase in dnmt5 (75%, n=30), dnmt6 
(100%, n=25), dnmt7 (70%, n=25) and dnmt8 (100%, n=20) morphants we saw 
that the expression of mpo was significantly unaltered in comparison to the 
control morphants. The expression of mpo in dnmt4 morphants at this stage was 
apparently mislocalized form the CHT region. The percentages represent the 








Table 3.1. Morpholino and primer sequences. 




dnmt4 e9i8 AGCCACCTGAGGACACACAGGAAGC 
dnmt4 e7i8 AGGCATTGTATTTTAGTTACCTCTG 
dnmt5 e2i2 TGTCTTTTACCCCTTACCTAGCATC 
dnmt6 e5i4 TGGCTACCTGTAAGACAAGACAGTC 
dnmt7 e3i2 TGCACCTAAAAACAAGACAAAACAG 
dnmt8 e12i13 ACATAATCTGAACTTACAAAGTCCT 
rdh1l e2i3 TCTGTCAGTGACTCACCCTTCTGTC 





Gene Forward Primer-1 Reverse Primer-1 
dnmt4-1   
dnmt4-2 
GATAATAAGGGCTTTGGTA
TTGG CTCAAGGGCCTGGAAGATC    
dnmt5 
ACACACTGACAACATCAAG
AG  tcagttcctcaacagcctat  
dnmt6  ATTCAGGTGGATCCAGGC CTGTTGCCTTTGAGTTCCTTC 





GACAG   
rdh1l GTCATCGCTGGCTGCTAC  CTCCAAGAGTACTGATCCTGC 
apc CGAAGCCAAACCAACACC  GCGTTGCTCACTATCGTC  
 Reverse Primer-2 Forward Primer-2 
dnmt4-1   
dnmt4-2 Cgtgattctgattggctgatg  
dnmt5 TGTCCAAATCCGACACCG  
dnmt 6   ATGGCTACAAATGTTAGTCTGG 
dnmt7  ATGGCTACAAATGTTAGTCTGG 
dnmt8  Cattcttgctgtgaggcaacagtg  
rdh1l gtcatagagcctgtactggc   























Values shown indicate the percentage of n embryos staining positively for the 
indicated marker. $n is the total number of embryos used in two or three different 
replicates of an experiment. Zebrafish genes are annotated in lowercase font 

























































































n/a   n/a   n/a n/a 
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EPISTATIC RELATIONSHIP BETWEEN DNA METHYLTRANSFERASE  
4 AND ADENOMATOUS POLYPOSIS COLI  
 
4.1 Introduction 
          Adenomatous polyposis coli (APC) is a large (310kDa) protein that has 
multiple functions in maintaining cellular homeostasis. Apc functions as a tumor 
suppressor and is also involved in cell adhesion, microtubule formation, 
regulating cell cycle and stability of chromosomes (1). Nearly 85% of all sporadic 
colon cancer cases have mutations in both the alleles of the APC gene (2). In the 
hereditary form of colon cancer, familial adenomatous polyposis (FAP), one 
mutated APC allele is inherited and loss of heterozygosity leads to 
tumorigenesis.  
           In addition to the molecular functions of Apc in maintaining intestinal 
homeostasis it is also expressed in the thymus, lymphocytes, and lymphobastic 
cell lines (3).The most well characterized and extensively used animal model for 
colon cancer is the ApcMin/+ mouse. Importantly, ApcMin/+ mice exhibit atrophy of 
the lymph and thymic nodes at 80 days (4). Around 120 days these mice exhibit 
a total regression of the thymus. These mice also exhibit depletion of splenic 
natural killer cells, immature and progenitor B cells suggesting that Apc may play 
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a role in hematopoiesis. However, why these mice start showing thymic atrophy 
at 80 days is not known. In a separate study, enhanced splenic hematopoiesis 
was observed at 12 and 15 weeks in ApcMin/+ mice (5). 
          Recent studies have also indicated the requirement of Apc in proper 
erythropoiesis (6). Mice with conditional removal of one allele of Apc exhibit 
severe anemia. Erythropoiesis is blocked in these mice at early stages of 
differentiation. These heterozygous mice have an expansion of long and short-
term hematopoietic stem cell populations. Myeloid progenitor cells are apoptotic 
suggesting that haploinsufficiency of Apc leads to impaired hematopoiesis. Also, 
this data hints at the possibility that loss of function of Apc may lead to 
myelodysplastic syndrome (6).  
          In a separate study ApcMin/+ mice were also shown to develop 
myeloproliferative phenotypes (7). The APC gene is located on chromosome 5q, 
and this region is commonly deleted in myelodysplastic syndromes.  Based on 
these data it is hypothesized that loss of function of APC may cause the 
phenotypes observed in myelodysplastic syndromes. 
          On deleting both the alleles of Apc in the hematopoietic compartment mice 
displayed severe bone marrow necrosis. The hematopoietic stem and progenitor 
cells in these mice showed rapid apoptosis, suggesting the requirement of Apc in 
hematopoietic stem and progenitor cell maintenance and survival. Also, these 




          The canonical function of APC includes regulating WNT signaling via 
proteasomal degradation of β-catenin (9). In addition to this function, loss of apc 
correlates with up-regulation of a DNA demethylase system and down-regulation 
of dnmt1 in the intestine of apc mutant zebrafish at 72h (10). Moreover, APC 
regulates retinoic acid biosynthesis through regulation of CtBP1 (11). 
Interestingly, up-regulation of the demethylase components in apc mutant 
zebrafish embryos results from the absence of retinoic acid signaling (10). 
Cumulatively, these studies underscore the genetic interactions between DNA 
methylation, DNA demethylation, retinoic acid biosynthesis and APC in regulating 
intestinal cell fating. However, the involvement of these key players in 
hematopoietic development has not been fully elucidated. 
          In Chapter 3, I show that dnmt4 is required for terminal differentiation of 
the erythroid and the myeloid lineage cells. Briefly, dnmt4 transcripts are robustly 
expressed in the hematopoietic compartment of zebrafish embryos. Knockdown 
of the transcript levels of dnmt4 using an antisense morpholino causes anemia 
and neutropenia in the morphant embryos at 72h. Interestingly, recent data 
suggests that not only are there distinct DNA methylation profiles in the 
developing human hematopoietic system, but also these epigenetic changes are 
affected by age (12).  
          Notably, the loss of Apc in murine hematopoietic cells leads to ineffective 
hematopoiesis affecting both the erythroid and the myeloid populations. 
However, the exact mechanisms that regulate this phenotype are not known. 
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Based on the findings in Chapter 3 and the data discussed above I hypothesize 
that loss of apc leads to ineffective hematopoiesis by down-regulation of dnmt4. 
          To test this hypothesis we have used apc mutant zebrafish line to show 
that apc mutant zebrafish embryos show a down-regulation of terminally 
differentiated erythroid and myeloid cells. Notably the apc mutant zebrafish 
embryos show a down regulation of dnmt4 transcripts in the hematopoietic 
compartment. The apc mutant embryos show mislocalization of mpo transcripts, 
which is rescued by the treatment of modulators of retinoic acid biosynthesis. 
However, treatment with WNT pathway inhibitor does not rescue this 
mislocalization, suggesting that the altered distribution of the mpo cells was 
through lack of retinoic acid biosynthesis. 
 
4.2 Materials and methods 
4.2.1. Zebrafish maintenance 
          Zebrafish stocks were maintained in z-mods on a 14:10 h light:dark cycle 
at 28°C in the Huntsman Cancer Institute  zebrafish fish facility using standard 
fish husbandry IACUC protocols. Fertilized embryos were grown at 28.5°C. For 
whole mount in situ hybridization embryos were raised in 0.003% phenylthiourea 







4.2.2. Oligonucleotides and constructs 
          The GenBank accession number for dnmt4 is NM_001025450. Zebrafish 
dnmt4 was cloned in pCRTOPOII vector. Michael Redd provided clones for mpx, 
cmyb and gata1, and Sarah Hutchinson provided clones for alphae1, alphae2, 
betae1, betae3. The sequence of the dnmt4 morpholino has been shown in 
Chapter 3. 
 
4.2.3. Whole mount in situ hybridizations 
          Zebrafish embryos at mentioned time points were fixed in sucrose buffered 
4% para-formaldehyde.  The embryos were washed in PBS, dehydrated and 
stored in methanol at -20°C.  Whole mount in situ hybridizations were carried out 
as described previously (13) using digoxigenin-labeled riboprobes for dnmt4, 
mpx, spi1, cmyb, gata1, alphae1, alphae2, betae1, and betae3. 
 
4.2.4. O-dianisidine staining 
          Hb activity was detected in whole embryos by histochemical staining for 
Hb using o-dianisidine as described previously (14). Briefly, embryos were 
placed in freshly prepared o-dianisidine stain solution (40% ethanol with 0.65% 
H2O2, 0.01 M sodium acetate, and 0.6 mg/mL o-dianisidine (D-9143; Sigma) for 
20 min and then were washed in water. Stained embryos were fixed in 80% 





4.2.5. Sudan Black staining 
          Sudan Black histochemical staining for detecting lipophilic mature 
neutrophils was performed as described previously (15). Briefly, embryos were 
fixed in 4% PBS for 2h at room temperature. Rinsed three times with PBS, 
incubated in Sudan Black (Sigma-Aldrich) for 20 min. The embryos were washed 
with extensively with 70% ethanol in water over 2h, then serially rehydrated to 
PBS and 0.1% Tween 20.  
 
4.2.6. Statistical analyses 
          Prism 4 (GraphPad Software, San Diego, CA) was used for statistical 
analyses. Results of statistical analyses are provided in supplementary Table S1. 
The quantitative data is representative of at least three independent experiments. 
 
4.2.7. Drug treatments 
          To rescue the retinoic acid deficiency apc mutants and control siblings 
were treated with 0.3µM all-trans-retinaldehyde (ATRAL; Sigma-Aldrich) at 10h, 
24h, 48h and 72h for 30 min. After each treatment the embryos were washed 
thrice with embryo water. To preclude the involvement of WNT signaling in the 
observed phenotypes, embryos were treated with an inhibitor of cox2 (NS-398) at 
10µM concentration 10h. The drug was allowed to remain in the media through 
72h. The embryos were allowed to grow until 72h and later fixed for in situ 
hybridization analyses. The apc mutant embryos harbor elevated levels of 
cyp26a1 a catabolic regulator of retinoic acid. To restore retinoic acid 
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biosynthesis in the apc mutant embryos they were treated with 5µM RAMBA, a 
pharmacologic inhibitor of cyp26a1, the levels of which are upregulated in apc 
mutants (16). 
 
4.2.8. PCR and expression analysis 
          Total RNA was harvested using Trizol reagent (Invitrogen) according to the 
manufacturer’s protocol. The RNA was treated with DNAse1 to remove gDNA 
contamination. cDNA for PCR reactions was synthesized from 2 µg of total RNA 
using Superscript III (Invitrogen). PCR was performed using the Roche 
Lightcycler instrument and software, version 3.5 (Roche Diagnostics). A 
template-free negative control was included in each experiment.  The sequences 
of PCR primers used: aid, mbd4, gadd45a, and 28s have been described 
elsewhere (10).  
 
4.3 Results 
          To determine if the apc mutant zebrafish embryos exhibit hematopoietic 
defects we investigated if they harbored terminally differentiated erythrocytes and 
neutrophil cells. The apc mutant zebrafish embryos exhibited sharp reduction in 
the o-dianisidine positive cells (Figure 4.1. upper panel), suggesting that they are 
anemic. However, the mRNA for progenitor blood cell populations like cmyb, 
gata1, alphae1, alphae2, betae1, and betae3 were expressed (data not shown).  
          Notably the apc mutants harbored fewer Sudan Black positive cells 
suggesting that lipophilic mature neutrophils were drastically reduced (Figure 4.1 
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lower panel); however, the mRNA transcripts for mpo were expressed robustly 
but mislocalized in the apc mutant embryos (Figure 4.2.). This suggested that 
although the progenitors were specified the terminally differentiated cell 
populations were drastically reduced. 
          To determine if the hematopoietic phenotypes that were observed in apc 
mutants was due to loss of dnmt4, we investigated the expression of dnmt4 in 
apc mutant embryos. We found that levels of dnmt4 were down-regulated in the 
CHT region of the apc mutant embryos suggesting that apc may regulate the 
expression of dnmt4 (Figure 4.3). However, the levels of apc were unaltered in 
dnmt4 morphants suggesting that dnmt4 does not regulate the expression of apc 
(Figure 4.4). 
          To determine if the altered distribution of the mpo cells was due to aberrant 
retinoic acid signaling we treated the embryos with retinaldehyde, RAMBA or the 
vehicle control DMSO (Figure 4.5). Interestingly the mislocalization of the mpo 
cells was rescued in the apc mutant embryos supplemented with RAL and 
RAMBA but not with NS-398 an inhibitor of cox2, suggesting that aberrant 
retinoic acid signaling and not overactive wnt is responsible for the this 
phenotype.  
          The rescue of mislocalization of the mpo positive cells in apc mutants with 
RAL and RAMBA suggests that retinoic acid is involved in terminal differentiation 
of erythroid and myeloid cells. To address if dnmt4 loss causes retinoic acid 
deficiency we performed quantitative RT-PCR to analyze the transcript levels of 
aid, mbd4 and gadd45a in the dnmt4 morphants. The dnmt4 morphants harbored 
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elevated level of aid, mbd4 and gadd45a suggesting that dnmt4 deficiency leads 
to retinoic acid deficiency (4.6). However, the mechanisms that cause this 
retinoic acid deficiency are not known. 
 
4.4 Discussion 
          The loss of function of Apc can lead to impaired functions of HSCs and 
HSPCs (8). Moreover, mice with heterozygous Apc show lethal anemia, 
monocytosis and macrocytosis between 3 to 8 months (6). Also, these mice 
exhibit a block in differentiation of erythroid development suggesting that Apc 
function may regulate hematopoiesis. Importantly, this anemia was not due to 
loss of blood, or vitamin deficiency suggesting that these cells failed to terminally 
differentiate into mature erythroid cells.  
          Moreover, it is not understood how these erythropoietic defects arise in 
these mice between particular ages that were reported. The DNA methylation 
profiles of cells that are arrested in differentiation are not known. Our data 
supports the notion that apc levels regulate dnmt4 expression in the 
hematopoietic compartment. However, if apc affects the transcription, translation 
or stability of dnmt4 is not known. Also, dnmt4 loss leads to retinoic acid deficient 
phenotypes, which can be rescued by retinoic acid supplementation. This is also 
corroborated by the rescue of mpo mislocalization in apc mutant zebrafish 
embryos. apc mutant zebrafish embryos are retinoic acid deficient (10,11,17), 
suggesting that retinoic acid may indeed play a role in regulating hematopoietic 
differentiation. However, it has still not been investigated if retinoic acid pathway 
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is directly regulated by dnmt4. Also it is not known if, retinoic acid regulates the 
expression of dnmt4. Figure 4.7 shows models that may explain the epistatic 
relationships between apc, dnmt4 and retinoic acid.  
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Figure 4.1. apc mutant zebrafish harbor anemia and  neutropenia at 72h. (A) 
apc mutant zebrafish show reduced staining for o-dianisidine suggesting that 
they suffer from anemia. (B) The apc mutant embryos exhibit a drastic reduction 










Figure 4.2. Transcripts for immature neutrophils (mpo positive cells) are 
expressed but their distribution is altered in the apc mutant embryos. At 
56h and 72h the apc mutant embryos exhibit an altered distribution of mpo. The 
transcripts are mislocalized to regions other than the CHT (as shown in the inset 
of the CHT region. However, it is not known what causes the mislocalization of 
these cells from the CHT and why there are reduced numbers of lipophilic mature 













Figure 4.3. The transcripts of dnmt are drastically reduced in the CHT 
region of the apc mutant embryos. Zebrafish dnmt4 transcripts are drastically 
down regulated in the CHT region of apc mutant embryos both at 56h and 72h. 
The inset shows the expression of dnmt4 in the CHT region at 72h in the mutant. 















Figure 4.4. The transcripts of apc are unaffected in the dnmt4 morphants. In 
the zebrafish dnmt4 morphants the transcripts of apc are unaffected suggesting 












Figure 4.5. The mislocalization of mpo positive cells in apc mutant embryos 
is rescued by pharmacological rescue of the retinoic acid pathway. At 72h 
the apc mutant embryos exhibit an altered distribution of mpo. The transcripts are 
mislocalized to regions other than the CHT. The exogenous supplementation of 
retinaldehyde and RAMBA (inhibitor of RA catabolic enzyme cyp26a1) rescues 
the mislocalization of mpo positive cells, suggesting a role of retinoic acid 
signaling in this process. However, inhibiting the over-active wnt signaling with 
supplementation of cox2 inhibitor NS-398 does not rescue this mislocalization 











Figure 4.6. Loss of dnmt4 in wild embryos with an antisense morpholino 
causes up-regulation of demethylase complex. Zebrafish dnmt4 
downregulation using an antisense morpholino causes upregulation of members 
of the demethylase complex in zebrafish aid, mbd4 and gadd45a as seen by in 
situ analyses of 72h dnmt4 morphants in the upper panel and by quantitative RT-
PCR analyses of the aid, mbd4 and gadd45a transcripts relative to the 























Figure 4.7. Putative models that represent the epistatic relationships 
between dnmt4, apc, and the retinoic acid pathway. The dnmt4 morphants 
harbor hematopoietic defects that are rescued by supplementation of retinoic 
acid. However, if retinoic acid affects the transcripts of dnmt4 is not known. apc 
mutants harbor similar hematopoietic defects to dnmt4 morphants. The 
transcripts of dnmt4 are down-regulated in the apc mutants. How apc affects the 
transcripts of dnmt4 is not known. The apc mutants and dnmt4 are both retinoic 
acid deficient. However the exact mechanisms that lead to retinoic acid 
deficiency in dnmt4 morphants are not known. The model suggested here has 




















Values shown indicate the percentage of n embryos staining positively for the 
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SUMMARY AND PERSPECTIVE 
 
5.1 Tissue-specific functions of dnmt1, dnmt3 and dnmt4 
DNA methylation is a reversible and heritable mechanism to silence 
genes. However, the examples of differentially methylated gene promoters during 
embryonic development are few (1, 2). It is hypothesized that DNA methylation 
occurs in a tissue-specific manner during embryonic development to confer cell-
specificity and cell-identity. However, examples of tissue-specific functions of 
DNA methyltransferases are largely unexplained. This specificity may perhaps 
arise in part because of the interacting partners of DNA methyltransferases that 
recruit them to different promoters to silence genes in cell- and tissue-specific 
manner. 
Identifying the target tissues of the different DNA methyltransferases, their 
interacting partners and their genetic targets will be important in discovering 
specific inhibitors of these enzymes. DNA methyltransferases may regulate 
common as well as discrete genes. Thus, to develop specific drugs it is important 
to identify both common and discrete molecular targets of these enzymes. 
The data presented in this thesis supports the idea that there are both 
discrete and common targets of the DNA methyltransferases (Figure 5.1). Using 
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an antisense morpholino approach we show that knock-down of dnmt1 (3), 
dnmt3 (4), and dnmt4 affects terminal differentiation of the exocrine pancreas 
and the retinal pigmented epithelium. However, terminally differentiation of the 
intestine (3), brain (4) and blood development are only affected in dnmt1, dnmt3, 
and dnmt4 morphants respectively. This suggests that these three enzymes 
affect the development of both similar and discrete organs. However, the factors 
that govern this tissue-specificity are not known. Importantly the genetic targets 
of each of these enzymes in the affected organs are still unknown. Also, the 
other DNA methyltransferases - dnmt5, dnmt6, dnmt7 and dnmt8 do not harbor 
similar hematopoietic defects like dnmt4 morphants suggesting a role of tissue-
specific development. 
 
5.2 Dnmt4 regulates zebrafish hematopoiesis 
 Stage specific methylation patterns have been shown to regulate gene 
expression in hematopoietic development (1). However, there is inconclusive 
data regarding the contributions of different DNA methyltransferases that may 
regulate hematopoietic lineages (5-7). In the present study we have identified 
that dnmt4 is a functional homolog of the mammalian DNA methyltransferase 3B. 
dnmt4 morphants partly phenocopy defects seen in the ICF syndrome occurring 
due to missense mutations in DNMT3B. dnmt4 regulates terminal differentiation 
of the erythroid and the myeloid blood cells. However, the molecular targets of 




5.3 Epistatic relationship between dnmt4  
and retinoic acid pathway 
          The findings reported in this study indicate that there is an epistatic 
relationship between dnmt4 and the retinoic acid pathway. The hematopoietic 
defects observed in dnmt4 morphant embryos are rescued by the exogenous 
supplementation of retinoic acid. Moreover, both genetic and pharmacologic 
knock-down of retinoic acid biosynthesis phenocopy hematopoietic defects seen 
in dnmt4 morphants. Interestingly, all-trans retinoic acid is administered as 
therapy for overcoming the differentiation block in acute promyelocytic leukemia 
cells (8).  
          However, the molecular events that regulate this rescue of differentiation 
block are not known. Important unanswered questions include- how does DNA 
methylation by dnmt4 regulate retinoic acid pathway? How does retinoic acid 
treatment recue defects observed in dnmt4 morphants? Does retinoic acid 
treatment induce the expression of dnmt4? Is there a feed-back loop between 
dnmt4 and the retinoic acid pathway? Answers to these questions are important 
with respect to the clinical use of DNA hypomethylating drugs (9) in 
myelodysplastic syndrome and retinoic acid-based therapy in hematological 
malignancies. 
 
5.4 Epistatic relationship between dnmt4 and apc 
APC is a large protein with multiple functions that regulate cell fate 
commitment. Our data suggests that apc positively regulates dnmt4 expression 
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in the hematopoietic tissues of the zebrafish embryos. apc mutant zebrafish 
embryos harbor similar hematopoietic defects as the dnmt4  morphants.  
Interestingly, the levels of apc are unaltered in the dnmt4 morphants. In our 
future experiments we will determine how apc regulates the expression of dnmt4. 
Also, investigations will be focused at determining how apc regulates the 
chromatin architecture via dnmt4 in the hematopoietic cells.  
 
5.5 Future directions 
           In summary, the important findings that have emerged from this thesis 
work are: 1) Zebrafish DNA methyltransferases 4, 5, 6, 7 and 8 are de novo DNA 
methyltransferases; 2) they have significant over-lapping yet discrete expression 
patterns in embryonic stages; 3) knockdown of the dnmt4, dnmt5, dnmt6, dnmt7 
and dnmt8 confers different gross phenotypic defects in these morphants that are 
distinct from each other; 4) dnmt4 morphants display cranio-facial and 
hematopoietic defects, some of which are also seen in ICF patients, 5) the 
defects seen in dnmt4 morphants can be rescued with catalytically active version 
of DNMT3B but not the inactive derivative; 6) dnmt4 morphants do not harbor gut 
and brain defects like dnmt1 and dnmt3 morphants. dnmt1 and dnmt3 morphants 
phenocopy dnmt4 morphants in harboring hematopoietic defects; 7) dnmt5, 
dnmt6, dnmt7, and dnmt8 do not harbor hematopoietic defects like dnmt4  
morphants; 8) retinoic acid deficiency in zebrafish phenocopies hematopoietic 
defects seen in dnmt4 morphants; 9) exogenous supplementation of retinoic acid 
rescues hematopoietic defects harbored in dnmt4 morphants; 10) dnmt4 levels 
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are down-regulated in the CHT region of apc mutant zebrafish embryos, and apc 
mutants display similar hematopoietic defects seen in dnmt4 morphants.  
      The three main themes that have emerged from the current dissertation work 
are: first, there is a requirement of DNA methyltransferases both in a distinct and 
overlapping tissue-specific manner to regulate differentiation, second, there is an 
epistatic relationship between DNA methylation and retinoic acid signaling; third, 
apc positively regulates DNA methylation.  
          The future plans for this study include parsing the above observations and 
themes. We plan to investigate the molecular functions of the different DNA 
methyltransferases in detail using loss-of-function approaches. We will identify 
the tissue-specific functions of dnmt5, dnmt6, dnmt7 and dnmt8. 
Complementation studies in conjunction with loss-of -function will help us to 
identify the homology between the zebrafish and human DNA 
methyltransferases. Also, we will investigate the homology between zebrafish 
genes and human splice variants. This will help us in deciphering the functions of 
the multiple isoforms of human DNMT3A and DNMT3B.  
          We will further identify the genetic targets of the different DNA 
methyltransferase in the specific organs by utilizing transgenic zebrafish lines to 
sort specific cell populations for mapping the methylome and transcriptome of the 
affected tissues in morphants. However, we still do not know the functions of the 
different DNA methyltransferases in the adult zebrafish. We also plan to 
investigate these questions. A detailed understanding of the tissue-specific 
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requirements of the different DNA methyltransferases will help us in designing 
better therapeutics against DNA methyltransferases.  
          To determine the molecular targets of dnmt4 in hematopoietic cells we will 
determine the transcriptome and methylome of myeloid lineage cells isolated 
from dnmt4 injected Tg:pu.1:GFP embryos. The other affected lineage in dnmt4 
morphants is the erythroid lineage. We will isolate the erythroid precursor cells 
from Tg:globin LCR:GFP embryos to determine the molecular targets of dnmt4  
in the red blood cell lineage cells.    
          Also, as proof of principle, to determine if DNA methylation conferred by 
DNMT3B is necessary for the terminal differentiation of the erythroid lineage 
cells, we will knock-down the levels of Dnmt3b in MEL (mouse erythro leukemia) 
cells. The Dnmt3b deficient MEL cells should not terminally differentiate into red 
blood cells in comparison to the control cells. Also, if retinoic acid signaling is 
deficient in the Dnmt3b deficient MEL cells then supplementation of exogenous 
retinoic acid will rescue the differentiation defects of these MEL cells. If DNA 
methylation conferred by DNMT3B in the erythroid cells is a conserved 
mechanism then as a proof of principle Dnmt3b deficient MEL cells will 
recapitulate the erythropoietic defects observed in zebrafish dnmt4 morphants. 
          We plan to pursue rigorous characterization of the dnmt4 morphants as a 
vertebrate model for ICF syndrome. Important future directions include 
characterizing the cytogenetic abnormalities and other molecular defects in detail 








Figure 5.1. Model showing dnmt4 function. The upper panel represents the 
transcriptional overlap of dnmt1 72h (red), dnmt3 72h (green) and dnmt4 72h 
(blue). Of all the genes analyzed only the two-fold up-regulated genes were 
plotted in this chart. This profile suggests that dnmt1, dnmt3, and dnmt4 may 
have both common and discrete target genes. However, the genetic targets that 
the different DNA methyltransferases silence in a tissue-specific manner are not 
known. The lower panel represents a schematic of promoter methylation by DNA 
methyltransferases 4 silencing a gene. However, the genes that are methylated 
by DNA methyltransferases, and proteins that recruit DNA methyltransferase 4 to 
its target genetic loci warrant further elucidation. It is hypothesized that dnmt4 
may regulate the expression of hematopoietic genes that may regulate terminal 
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Figure A.1. Methylated DNA binding proteins and DNMTs. Methylated DNA 
binding proteins (MBDs) are considered as readers of the DNA methylation mark. 
The MBD proteins have a methyl-binding motif-MBD domain, a transcriptional 
repression domain-TRD and a cysteine rich domain –CxxC motif. All of the MBD 
proteins apart from MBD3 can bind methylated DNA. These proteins bind 
methylated DNA with the help of MBD motifs with the exception of Kaiso a 










Figure A.2. Characterization of mbd1 knockdown in zebrafish embryos. The 
upper panel shows the domain structure of the mbd1 protein in zebrafish. The 
middle panel represents the design of the morpholino and the primers used for 
confirming splice check in the mbd1 morphants at 24h. The lower panel shows a 






























Figure A.3. Bulk methylation levels in mbd1 morphants. The Y-axis in the 
graph represents the % 5mC levels (bulk cytosine methylation level) in mbd1 and 
wild type control embryos at 24h and 72h. There is no apparent change in the 
bulk methylation levels on knocking down mdd1 suggesting that mbd1 is not 
involved in maintaining the bulk methylation levels in zebrafish embryos. 
However, it will be interesting to determine if there are subtle changes in the 











Figure A.4. Expression pattern of mbd1 in zebrafish. The transcripts of mbd1 
are maternally supplied. mbd1 is ubiquitously expressed in earlier time points. At 
around 48h the expression is more robust in the eyes and the head. At 72h the 
expression of mbd1 is restricted to the gut (yellow arrow), pancreas (white 
arrow), thymi (blue arrow), tegmentum (red arrow) and eyes (green arrow). The 
expression pattern of mbd1 morphants suggests that it may be involved in 











Figure A.5. The gross morphological phenotype of mbd1 morphant 
embryos at 72h. On knocking down the levels of mbd1 zebrafish embryos an 
interesting phenotype was observed. The 70% of embryos exhibited a cork screw 
shape phenotye at 48h and 72h. A similar phenotype is observed in atp7a mutant 
calamity. Atp7a is a gene that posses a CXXC motif like mbd1. It will be 











Figure A.6. Characterization of mbd3a and mbd3b knockdown in zebrafish. 
The upper panel shows the domain structure of the mbd3 proteins in zebrafish. 
The middle panel shows the reduction in formation of spliced product in the 
morphant embryos in comparison to the control embryos. The lower panel 
represents the design of the morpholino and the primers used for confirming 












Figure A.7. Expression pattern of mbd3a and phenotypes of mbd3a 
morphants. The transcripts of mbd3a are maternally supplied and are 
ubiquitously expressed at all time points during development suggesting that it 
might have important functions in embryonic development. The upper panel 
shows the gross morphological defects of mbd3a morphants at 72h. The 
morphant displays a smaller head, closer set eyes (suggesting jaw defects), 








Figure A.8. Expression pattern of mbd3b and phenotypes of mbd3b 
morphants. The upper panel represents the expression pattern of mbd3b. The 
transcripts of mbd3b are maternally supplied and are ubiquitously expressed at 
early time points like 10h. At 24h the expression is robust in the neural tissues 
and the notochord. At 48h, 72h and 96h the expression is very restricted to the 
anterior structures like the eyes, brain pharyngeal arches and the pectoral fin. 
Interestingly, the knockdown of mbd3b does not show an apparent phenotype in 










COMPARISON OF OVEREXPRSSION AND  








Figure B.1. Comparison of over-expression and knock-down of dnmt4 . The 
upper panel (A) shows over expression of 0.15 pg of dnmt4 RNA in wild type 
embryos. The embryos at 72h show abnormal yolk sac (green arrow) in 
comparison to uninjected control embryo in (B). Also the heart appears more 
looped than the uninjected embryo heart in (A). The embryos display strong 
pericardial edema and accumulation of RBC. In the lower panel (C) the dnmt4 
morphants display pericardial edema and hypochromic blood cell. The looping of 
the heart appears to be disrupted (red arrow). Also, the morphant embryos 
display lack of yolk sac extension. 
